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Abstract__________________________________________________________ Il
Abstract
The microorganisms constituting the Mycobacterium tuberculosis complex are 
associated with important human and animal diseases. Mycobacterium tuberculosis 
is estimated to infect a third of the world’s population whilst Mycobacterium bovis is 
a zoonotic pathogen primarily infecting cattle and other livestock. M. bovis is thought 
to have evolved from a M. tuberculosis-Wke ancestor and is itself the ancestor of the 
BCG vaccine strain, Mycobacterium bovis BCG. These mycobacteria demonstrate 
distinct differences in virulence, host range and metabolism, but the role of 
metabolic differences in pathogenicity is unknown. Systems biology approaches 
have previously been applied to investigate the metabolism of M. tuberculosis but 
not to probe differences between strains within the complex.
Genome scale metabolic networks of M. bovis and M. bovis BCG were constructed 
based on genome annotation, biochemical data and detailed bioinformatics 
analyses. The networks (in parallel with an updated M. tuberculosis network) were 
interrogated by flux balance analysis to predict growth rates, substrate utilisation 
and gene essentiality, with the predictions compared against high-throughput 
phenotype and published gene essentiality data. The models correctly predicted 87 - 
91% of substrate utilisation data, 75 - 77% of gene essentiality data and in silico- 
predicted growth rates closely corresponded with in w'fro-measured substrate 
consumption and growth rates. The comparisons also revealed discrepancies 
between in silico predictions and in vitro data, highlighting areas of incomplete 
metabolic knowledge. Several of these discrepancies were examined by 
experimental studies revealing novel insights into metabolism that may be relevant 
to mycobacterial pathogenicity. Information discovered from the analysis of these 
models, along with additional published literature, was used to update and expand 
the original networks. These networks also successfully simulate many aspects of 
the growth and physiology of the M. tuberculosis, M. bovis and M. bovis BCG strains 
and provide an invaluable tool for their study.
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1.1 Introduction
The pathogenic microorganisms constituting the Mycobacterium tuberculosis 
complex (MTC) are associated with important human and animal diseases. 
Mycobacterium tuberculosis, the causative agent of human tuberculosis, is 
estimated to infect one third of the world’s population and cause the deaths of 1.4 
million people each year (1), whilst the closely related pathogen Mycobacterium 
bovis infects a wide range of mammals (2, 3). In an attempt to prevent human 
tuberculosis infection more than 3 billion individuals (4) have been immunised with 
Mycobacterium bovis: Bacillus Calmette-Guérin {M. bovis BCG), a live attenuated 
derivative of M. bovis. M. tuberculosis, M. bovis and M. bovis BCG are characterised 
by >99.95% similarity at the nucleotide level (4-6). However, the genetic deletions, 
rearrangements and duplications that M. bovis and M. bovis BCG have undergone 
relative to M. tuberculosis results in widely differing metabolic phenotypes, 
pathogenicity and host tropisms (2-7). The genetic basis of these profound 
variations are mostly undefined. Defining and gaining a more complete 
understanding of the metabolism and metabolic differences between the three 
species is of particular importance as metabolic adaptation to the host environment 
has been highlighted as a key component of the pathogenic strategy of 
M. tuberculosis (8-13) and is also likely to be important for the virulence of M. bovis. 
Although there have been targeted investigations into the metabolic differences 
between the human and bovine tubercle bacillus, systems level studies have not yet 
been undertaken.
1.2 Genus Mycobacterium
M. tuberculosis, M. bovis, and M. bovis BCG are in the genus Mycobacterium, which 
is the only member of the family Mycobacteriaceae within the order 
Actinomycetales. Species within the genus are predominantly saprophytic, although 
highly successful human and zoonotic pathogens (such as M. tuberculosis and 
M. bovis) are also included. Both environmental and pathogenic mycobacteria are 
widely distributed in nature with saprophytes particularly residing in soil and water 
and pathogenic mycobacteria infecting a wide range of animals.
Mycobacteria are characteristically aerobic. Gram-positive, predominantly 
non-motile, rod-shaped bacilli that contain an unusually high GC content (62 - 70%)
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and are between 0.2-10 pm in size, depending on the culturing technique. Despite 
classification as Gram-positive, mycobacteria are distinctive due to the absence of a 
traditional outer membrane and the presence of a hydrophobic, waxy cell wall, rich 
in mycolic acids and mycolates. These unique structural properties result in specific 
‘acid fast’ staining characteristics, where, once stained with basic dyes (e.g. carbol 
fuchsin) addition of acid doesn’t result in discolouration.
Traditionally mycobacteria have been phylogenetically assembled based on growth 
rate and pigmentation, but recent classifications are cladistic based and utilise DNA 
sequencing, phenotyping and rRNA sequences. Within this system some species 
are grouped into complexes based on genetic relatedness, such as the MTC.
1.2.1 Mycobacterium tuberculosis complex
The mycobacteria comprising the MTC {M. tuberculosis, Mycobacterium africanum, 
M. bovis, M. bovis BCG, Mycobacterium microti, Mycobacterium caprae, 
Mycobacterium canettii, Mycobacterium pinnipedii and Mycobacterium mungi 
(Figure 1-1)) are characterised by >99.95% DNA similarity and identical 16S rRNA 
sequences (14). Apart from M. bovis BCG (a sub-species of M. bovis) all species 
are pathogenic and the causative agents of tuberculosis infection in either humans 
or animals.
The MTC is thought to have emerged from a Mycobacterium prototuberculosis 
progenitor pool (15) approximately 40,000 years ago; around the time modern 
human populations dispersed from the Horn of Africa (15). The complex split into 
two lineages between 20,000 and 10,000 years later with clade one exclusively 
human and clade two also able to infect animals (15). Clade two includes all MTC 
species bar M. tuberculosis and M. canettii (15). The spéciation of MTC strains from 
their common ancestor occurred by reductive evolution, with successive loss of DNA 
sequences and single nucleotide polymorphisms (SNPs) resulting in the evolution of 
separate species (Figure 1-1). Clade one mycobacteria are thought to have 
undergone far fewer genetic deletions than clade two species. Whilst the functional 
impact of these deletions in unknown; they do however serve to mark the clones 
(16).
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Figure 1-1: The proposed evolutionary scenario of the Mycobacterium tuberculosis complex
(16)
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1.2.2 Mycobacterium tuberculosis
M. tuberculosis is one of the world’s most successful pathogens and the primary 
causative agent of tuberculosis infection in humans. Currently, epidemiologists 
estimate that one-third of the world’s population is infected with M. tuberculosis, with
1.4 million deaths and 9.2 million new cases occurring annually (1). Despite the 
initial high level of success achieved by the variety of drugs available for the 
treatment and control tuberculosis, the use of antimicrobials has become 
increasingly compromised due to the emergence and spread of resistance. 
Multidrug-resistant (resistance to at least isoniazid and rifampicin) and extensively 
drug-resistant (resistance to second line anti-tuberculosis drugs) M. tuberculosis 
strains have emerged, with estimates for the percentage of isolates around 20%
(17) and 10% (17) respectively. Recently, totally drug-resistant M. tuberculosis 
strains have also been reported (18-20). In addition, hypervirulent strains, such as
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the W-Beijing family, have also recently emerged and are often responsible for 
outbreaks of infection (21).
M. tuberculosis is an almost exclusively human pathogen and is highly adapted to 
life within its host. It is renowned for the ability to facilitate latent infection, which is 
defined as the persistence of bacteria in the absence of clinical symptoms. 
Tuberculosis is most commonly transmitted by the inhalation of small aerosolised 
cough droplets containing the tubercle bacilli and implantation can lead to several 
potential outcomes: immediate elimination, latency, or the development of active 
disease. In around 50 - 75% of tuberculosis contacts the bacteria are killed and 
eliminated by the innate immune system (22), 25 - 50% of cases result in bacterial 
replication in the pulmonary site and in the regional lymphatics and 5 - 10% of 
infected individuals develop active disease within 2 years of initial infection (23).
Tuberculosis is a granulomatous disease that usually establishes primary infection 
in the lungs. Once in the pulmonary alveoli the mycobacteria are phagocytised by 
macrophages and are able to replicate within them by preventing phagosomal- 
lysosomal fusion and acidification of the phagosome. During initial infection the 
bacilli can escape from the macrophages and disseminate via the bloodstream to 
set up multiple foci of infection. Around the site of infection, macrophages, 
T lymphocytes, B lymphocytes and fibroblasts aggregate to form granulomas. In 
most immunocompetent individuals this cell mediated response prevents 
mycobacterial dissemination resulting in latent infection. Immunosuppression can 
result in the re-activation of the infection, ensuing progression to active disease. 
Symptoms of active pulmonary tuberculosis are coughing, sometimes with sputum 
or blood, chest pains, weakness, weight loss, fever and night sweats.
1.2.3 Mycobacterium bovis
M. bovis is the causative agent of bovine tuberculosis (bTB) and primarily infects 
cattle and other livestock. It has the broadest host tropism of any of the 
mycobacteria and is also capable of infecting a wide range of mammals and 
vertebrates, including humans (2, 3). bTB establishes reservoirs amongst wildlife 
and domesticated populations with wild animals maintaining the sylvatic cycle of 
tuberculosis and domestic animals continuing the infection in agricultural 
communities. Infection of cattle is considered one of the biggest challenges facing
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the farming industry today and it is thought badgers, first identified as carriers of 
M. bovis 30 years ago, play a major role in maintaining M. bovis infection in cattle 
(24). Badgers transmit bTB to cattle either directly, through contact with excreta or 
via the inhalation of aerosols, as badgers excrete M. bovis in exhaled air, sputum, 
urine, faeces and pus. bTB causes immense economic loss in many countries, 
either from loss of livestock, disease testing, or compensation, and worldwide 
agricultural losses are estimated to be around $3 billion a year (6, 25). In the UK 
M. bovis incidence in cattle has undergone a steady, continuous increase from the 
mid-1980s with an exponential increase in Southwest England (6). In 2005 bTB cost 
the UK economy around £90.5 million (26).
Although primarily recognised as an animal pathogen, M. bovis also constitutes a 
significant public health risk due to its ability to infect humans. The risk to human 
populations is varied, depending on the epidemiological situation. Humans in 
constant contact with infected animals, such as farmers and veterinarians may 
become infected, but historically it was the consumption of unpasteurised milk or 
insufficiently cooked meat from infected cattle that was the greatest source of animal 
to human transmission. In the developed world bTB control strategies have 
drastically reduced the incidence of disease (27), but in developing countries 
M. bovis infection can still be endemic. In Great Britain surveillance, slaughterhouse 
inspections and milk pasteurisation have been implemented since 1935 and these 
control measures have resulted in bTB being considered a negligible public health 
problem (28). Currently, the percentage of tuberculosis infections due to M. bovis is 
1% (29), as compared to 6% (30) before any bTB control strategies were 
implemented. Little data is available on rates of M. bovis infection in the developing 
world, as it is not possible to clinically differentiate between tuberculosis caused by 
M. bovis and that caused by M. tuberculosis. Therefore, diagnostic tests are 
required which are either not feasible or a priority within health care systems.
1.2.4 Mycobacterium bovis BCG
M. bovis BCG is a live attenuated vaccine strain derived from M. bovis in the early 
1900s. It is currently the only available vaccine against tuberculosis infection and is 
used to stimulate the immune system into mounting an attack via the principal of 
cross reacting antigens. The BCG vaccine is one of six vaccines in the World Health 
Organization’s (WHO) expanded program of immunisation with immunisation
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mandatory in M. tuberculosis-en6em\c areas (4). Consequently the BCG is the 
world’s most widely used vaccine.
The BCG vaccine originated with the parent strain ‘lait Nocard’, a virulent strain of 
M. bovis isolated from the milk of a cow suffering from tuberculosis mastitis in 1901 
(31). Albert Calmette and Camille Guerin used lait Nocard to study tuberculosis at 
the Institute Pasteur in Lille, France and serially passaged the strain on 
glycerol-soaked potato slices. Within a few months this technique had resulted in the 
isolates acquiring unusual colony morphology and reduced virulence in guinea pigs. 
As a result of this observation Calmette and Guerin continued the in vitro serial 
passage (230 passages) for 13 years (1908 - 1921) in an attempt to create an 
efficient vaccine. During these years numerous experiments to establish both 
efficiency and safety were carried out, and in 1921 the first child was immunised 
with the BCG (31). Since the child didn’t develop M. tuberculosis or experience 
deleterious side effects vaccination of newborns continued and by 1924 the Institute 
Pasteur had begun to distribute the vaccine around the world (32). As a result of its 
success immunisation campaigns were implemented throughout Europe, with the 
WHO recommending their expansion worldwide after World War II.
As a live vaccine, transfer of M. bovis BCG cultures was a repeated occurrence, and 
despite efforts to standardise the growth and preparation of the vaccine, passaging 
resulted in continued in vitro evolution of the BCG vaccine. Consequently, dozens of 
distinct daughter strains emerged, meaning that the BCG vaccine refers to a family 
of different substrains (33-36). The process of in vitro evolution began to be halted in 
1966 by the ‘seed lot system’ of BCG lyophilisation, introduced as part of the 
‘requirements for dried BCG vaccine’ initiated by the WHO. There are many BCG 
daughter strains with the four currently in major use being: BCG-Pasteur (1173P2), 
BCG-Japan (Tokyo-172), BCG-Danish (Copenhagen-1331) and BCG-Glaxo (1077).
Despite its success and inclusion in WHO initiatives, the BCG vaccine is a 
controversial vaccine due to several clinical studies questioning its efficacy at 
preventing M. tuberculosis in adults. Despite its proven efficacy at preventing extra- 
pulmonary tuberculosis in children (37), in adults its efficacy against pulmonary 
disease is variable (0 and 85%) (38-40). Several theories relating to the failure of the 
BCG have been proposed such as: genetic factors, the BCG sub-strain used and 
prior sensitisation with environmental mycobacteria (which are very common in
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tropical areas) (40-42). Consequently new vaccines, such as recombinant BCGs, 
live attenuated M. tuberculosis, other mycobacteria (JMycobactenum. vaccae) and 
viral vector vaccines are being investigated as potential vaccine candidates.
1.3 Genomics
Genomics is the study of an organism’s genome and involves the convergence of 
many science disciplines, including genetics, molecular biology, biochemistry and 
computer sciences. Genome analysis represents a crucial component of 
microbiological investigations due to the vast array of information that a genome 
sequence provides. For instance, bacterial biochemistry and evolutionary history 
can be deduced, and comparison between pathogenic and vaccine strains offers an 
insight into the basis of disease. Consequently, genomic data has the potential to 
identify novel drug targets or more optimal vaccines, and the exploitation of genetic 
sequences is of major scientific interest.
1.3.1 Mycobacterial genomes
The MTC complex strains M. tuberculosis, M. bovis and M. bovis BCG have 
>99.95% DNA similarity with all three genomes showing co-linearity, a stable GC 
content (66%) and no evidence of extensive translocations, duplications or 
inversions (4-6). Horizontal transfer of genetic material does not occur, with any 
horizontal transfer having occurred in ancient evolutionary events. Sequence 
analysis has thus far assigned a gene function to around 60% of genes (4-6) with 
30% of detected enzymatic activities not currently ascribed to a known gene (43). Of 
the strains to be used in this study, M. tuberculosis H37Rv, the most widely used 
strain of M. tuberculosis (5), has the largest genome at 4,411,529 bp and 4,043 
genes (5). M. bovis AF2112/97 has the smallest genome, at around 91 genes 
smaller than M. tuberculosis H37Rv (4,345,492 bp and 3,952 genes) (6), and 
M. bovis BCG has a genome of 4,374,522 bp and 3,954 genes (4).
1.3.2 Reductive evolution
The reduction in genes and genome size shown by M. bovis as compared to 
M. tuberculosis is due to the regions of difference (RD) that have occurred during its 
evolutionary passage (Figure 1-2). RD are DNA regions predominantly involving
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deletion mutations, that occur in M. bovis, M. bovis BCG or M. tuberculosis as 
compared to each other. Their identification enabled the current evolutionary theory 
of reductive evolution, with M. tuberculosis is placed closer to a common ancestor 
(16), to develop from the previous hypothesis that M. tuberculosis evolved from 
M. bovis due to its restricted host range. Before comparative genomics, 
hybridisation-based methods recognised the presence of 11 RD (RD4, RD5, RD6, 
RD7, RD8, RD9, RD10, RD11, RDI 2, RDI3) which are absent in all strains of 
M. bovis as compared to M. tuberculosis and range from 1 -12.7 kb in size (44-47). 
Small RD (RvD and TbDI (44, 45, 48)) are also present in M. tuberculosis H37Rv. 
In addition to these RD the availability of genome sequencing enabled many 
smaller, and often M. bovis lineage specific, RD and SNPs to be discovered (49). 
There are 2,437 (6) SNPs between M. bows AF2122/97 and M. tuberculosis H37Rv 
with an unexpectedly high frequency of non-synonymous to synonymous changes 
(6).
Figure 1-2; Genealogy of M. tuberculosis, M. bovis and BCG vaccines (4)
The diagram shows some of the RD markers, strain-specific deletions, and the distribution of 
vaccines into the four groups
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In addition to the RD found in M. bovis, M. bovis BCG strains have a further 5 main 
deletion events (RDI, RD2, RD3, RDI4, RDI5, RDI6 (4, 44, 45, 50)) (Figure 1-2) 
as well as other variable regions including smaller deletions, tandem duplications 
(DU) and SNPs (4, 44, 50-52). Apart from the RD there are also 736 (4) and -2,400 
(4) SNPs between M. bovis BCG Pasteur and M. bovis AF2122/97 and 
M. tuberculosis H37Rv respectively. Unlike with M. tuberculosis or M. bovis most 
RDs and SNPs found in M. bovis BCG are lineage or strain specific (44, 50-53) due 
to their distribution around the world early in their evolutionary history. 
Consequently, BCG substrains exhibit extensive genotypic diversity (Figure 1-2).
1.3.2.1 BCG Vaccine attenuation
Despite knowledge of M. bovis BCG specific mutation events, the precise 
determinants of attenuation are mostly undefined. RDI and RD2 have been 
implicated in loss of virulence, as have SNPs (54-59). RDI is a 9.8 kb genomic 
deletion which is the only confirmed RD that occurred before clinical use of the BCG 
vaccine in 1921 (44). RDI comprises nine genes (Rv3871 - Rv3879c) and encodes 
part of the ESAT-6 secretion system-1 (ESX-1) protein secretion system, a recently 
discovered type VII protein export pathway. The implication that the loss of RDI 
contributes to BCG attenuation has been confirmed by both gene disruption (55) 
and complementation experiments (56) and is also associated with the loss of 
secretion of culture filtrate protein 10 and ESAT-6, a 6-kDa early secretory antigenic 
target (58-60). However, full pathogenicity of M. bovis BCG Pasteur is not restored 
upon complementation with RDI (54, 57). Consequently, this suggests that 
additional genetic lesions, potentially involving the accumulation of SNPs or the 
downregulation of protein antigens MPB64, MPB70 and MPB83 (61) contribute to 
the attenuation of the BCG vaccine. Late M. bovis BCG strains have also lost the 
RD2 region which has been attributed to the further attenuation reported between 
the years 1927 and 1931 (62-64).
1.3.3 Comparative genomics
Functional genomics aims to understand gene function and the relationship between 
an organism's genome and its phenotype. This is of particular importance in 
M. tuberculosis, M. bovis and M. bovis BCG because although M. bovis and
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M. bovis BCG have undergone comparatively few genetic deletions, rearrangements 
and duplications relative to M. tuberculosis, these genetic differences result in widely 
differing host tropisms, phenotypes and pathogenicity. Due to the vast amount of 
information that genome sequences and the accompanying experimental techniques 
provide, establishing the genome sequence of M. tuberculosis (H37Rv (5), 
CDC1551 (65), Erdman (66)), M. bovis (AF2122/97 (6)) and M. bovis BCG (Pasteur 
(4), Tokyo (67) Moreau (68), China (69), Danish (69), Russia (69) and Tice (69)) has 
led to a greater understanding of the metabolism of these mycobacteria. However, 
despite these advances our understanding is still very incomplete and mainly based 
on gene annotations assigned due to sequence similarity with enzymes in other 
organisms.
1.4 Mycobacterial metabolism
Before genome sequencing analysis of cellular extracts identified numerous enzyme 
activities, but this approach gave a fragmented overview of metabolism due to the 
huge number of cellular enzymes. The availability of annotated genome sequences 
more thoroughly determined the metabolic capabilities of these mycobacteria, but 
still presents an incomplete picture of their metabolic capabilities. Through both 
cellular and genome analysis M. tuberculosis, M. bovis and M. bovis BCG have 
been shown to have many classical metabolic pathways involved in lipid and central 
carbon metabolism (CCM), the potential to synthesise every amino acid, metabolise 
a variety of carbohydrates, hydrocarbons, alcohols, ketones and carboxylic acids 
and transcribe a large number of oxidoreductases, oxygenases and 
dehydrogenases (5, 40, 70). However, despite advances in understanding 
mycobacterial metabolism many aspects, especially the regulation of CCM, remain 
unclear. The current lack of certainty is due to the inherent error in homology-based 
gene annotation, the fact that reaction connectivity and directionality are not 
addressed by sequencing, difficulties in detecting the activity of some enzymes and 
gaps in our knowledge of how substrate catabolism regulated (71).
1.4.1 Metabolic differences
In 1896 Theodore Smith became the first person identify biochemical differences 
between M. tuberculosis and M. bovis (72). Historically, these metabolic differences 
were used to differentiate between the human and bovine bacilli, even though it was >
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not until 1970 that they were officially declared as separate species (73). 
Differentiation was based on the fact that M. bovis is unable to grow in glucose or 
glycerol media (74) (the preferred carbon source for M. tuberculosis when grown in 
laboratory conditions), produces less niacin (75-78) and is R-glucosidase negative 
(79). As a result of genome annotation the basis of these, and many more 
differentiating metabolic features, have been identified; some in key pathways such 
as CCM, amino acid and lipid metabolism (Figure 1-3). The metabolic defects are 
primarily in M. bovis and M. bovis BCG as reductive evolution has resulted in the 
loss of enzyme activities, whilst M. tuberculosis remains genetically closer to their 
common ancestor (16). Defining and gaining a more complete understanding of the 
metabolic differences between these three species is of particular importance as 
survival within host tissues appears to be related to metabolic reorientation. 
Therefore, for a greater understanding of mycobacterial pathogenesis it is crucial to 
determine the metabolic capacity, limitations and differences between 
M. tuberculosis, M. bovis and M. bovis BCG.
Figure 1-3: Schematic of some of the metabolic differences between M. bovis AF2122/97 
and M. tuberculosis H37Rv (6).
The blue and red lines represent the cell wall of M. tuberculosis and M. bovis respectively. 
Surface-exposed and transport molecules are shown embedded In the wall.
Differentially secreted proteins (orange arrows) are shown In each half.
The Interior of the diagram shows the key steps In carbohydrate metabolism, with the red 
crosses showing where lesions occur In M. bovis.
Proteins that Interact with DNA which are Inactivated In M. bovis are shown In blue.
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The most prominent distinction between the species dictates that growth media for 
M. bovis must be supplemented with alternative carbon sources to glucose and 
glycerol, traditionally pyruvate. This requirement is due to an inactive pyruvate 
kinase (6, 80, 81) (pykA) (interconversion of phosphoenolpyruvate and pyruvate) 
which results in the inability of glycolytic intermediates to enter the Tricarboxylic acid 
cycle (TCA cycle). Additionally some M. bovis strains, including M. bows AF2122/97, 
also possess an inactive glycerol kinase (6, 80) {gIpK) (interconversion of glycerol 
and glycerol 3-phosphate) further preventing growth on glycerol. During the serial 
passage of the BCG vaccine, selection pressure for the utilisation of glycerol 
reversed the inactivating mutation present in pykA and resulted in the ability of 
M. bovis BCG, unlike M. bovis, to use glycolytic intermediates for energy generation 
(4).
Other metabolic differences in central pathways include inactivating mutations in the 
amino acid pathways of alanine, glycine and serine. In M. tuberculosis alanine 
dehydrogenase {aid) catalyses the oxidative deamination of alanine or, in the 
reverse direction, the reductive amination of pyruvate to yield alanine; but this 
activity is lost (6, 81, 82) in M bovis and M. bovis BCG due to a fra mesh ift caused 
by single base pair deletion. Aid has also been found to catalyse the conversion of 
glyoxylate to glycine, and therefore this activity has been lost in M. bovis and 
M. bovis BCG (83). In addition, M. bovis BCG Pasteur and other late strains have 
lost L-serine deaminase (sdaA) (the interconversion of pyruvate and serine) activity 
due to inadequate expression levels.
1.4.2 Metabolism and pathogenicity
The metabolism of M. tuberculosis has been an area of intense interest as metabolic 
adaptation to the host environment has been highlighted as a key component of the 
pathogenic strategy of M. tuberculosis, and is also likely to be important for the 
virulence of M. bovis. M. tuberculosis, and presumably M. bovis, show significant 
metabolic flexibility that allows adaptation to various environmental conditions, such 
as nutrient starvation, oxygen deprivation and various exogenous stress conditions 
(84-88). This metabolic plasticity is thought to enable the microorganism to survive 
within the changing and adverse host environment during both the acute and 
chronic phase of infection. Particular metabolic pathways such as CCM and lipid
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degradation have been shown to affect the virulence of M. tuberculosis, but despite 
being identified as an important aspect of mycobacterial infection, the precise 
function of metabolism and metabolic genes in infection is relatively unknown.
1.4.2.1 Central carbon metabolism and pathogenicity
The implication of CCM (glycolysis, gluconeogenesis, the TCA cycle, glyoxylate 
shunt and several anaplerotic enzymes) (Figure 1-4) in the pathogenicity of 
M. tuberculosis indicates that it has evolved to serve a pathogenic purpose that is 
independent of its crucial physiologic roles. Pathogenic functions are implied 
because genetic evidence has identified the CCM as a key determinant of 
M. tuberculosis’s pathogenicity (89, 90) and a number of genes that are conditionally 
required for in vitro growth cause profound attenuation of infection when disrupted in 
vivo (9-13, 90-92). Isocitrate lyase {id] glyoxylate shunt), phosphoenolpyruvate 
carboxykinase (pepc/c; anapleurotic), fructose 1, 6-bisphosphatase (g/pX; 
gluconeogenesis), dihydrolipoamide acyltransferase (d/aT; glycolysis) and lipoamide 
dehydrogenase (/pcf; glycolysis) are required for growth and persistence in in vivo 
mice models and macrophages®'^ ’^ Id  and pepck are also upregulated in 
persistence phase bacilli during mouse infection and form part of the extensive 
alterations to gene transcription occur during infection (8, 93).
1.4.2.2 Lipid metabolism and pathogenicity
Lipid metabolism is also thought to be an important aspect of mycobacterial infection 
and it has been suggested that pathogenic mycobacteria may be lipolytic with lipids 
as the major carbon source in the host (40, 94-97). The dependence of 
M. tuberculosis on lipids during host infection is implied by the large number of 
enzymes involved in fatty acid degradation (5), the importance of genes involved in 
lipid catabolism for virulence in the lungs of mice and macrophages {mce-A, id, 
pepck, gipX) (9, 10, 13,91, 92, 95, 98), the upregulation of genes involved in lipid 
metabolism in vivo (8, 99, 100) and ex vivo M. tuberculosis preferably metabolising 
fatty acids (101). Lipolysis may also be implied by the inability of glycolytic 
intermediates to enter the TCA cycle in M. bovis. M. bovis must rely on fatty acids or 
amino acids for energy generation in the host (6) and since M. bovis and 
M. tuberculosis cause clinically indistinguishable diseases their substrate 
requirements are likely to be similar.
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Figure 1-4: Central carbon metabolism and other central degradation pathways in 
M. tuberculosis (102)
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1.5 Systems approaches to metabolism
Systems biology focuses on the complex interactions within biological systems, and 
how the interconnected nature of components gives rise to the behaviour of the 
system. This approach, enabled by recent advances in computational biology and 
high throughput experimental technologies, provides very effective methods for 
studying metabolism due to its dynamic interconnectivity. Traditionally, metabolic 
studies were limited to the analysis of individual genes or enzymes. These studies, 
whilst providing useful information, can lead to the overestimation of the importance 
of metabolic components as enzymes function as part of a system rather than in 
isolation. Systems biology and accompanying high-throughput technologies, such as 
genome sequencing and annotation, has enabled metabolism to be studied on a 
genome scale.
1.5.1 Genome scale reaction networks
Genome scale metabolic reaction networks represent cellular metabolism by 
incorporating all known biochemical reactions within a cell, and by using computer 
simulations to extract information from the reconstructed network. They represent a 
global system where metabolic pathways and their respective reactions and genes 
are analysed within the context of whole cell metabolism. The reaction network is 
constructed from genome annotations which predict the enzymes, reactions and 
pathways present within the cell; and the network utilises a constraint-based 
modelling approach, such as flux balance analysis (FBA), where metabolite 
concentrations are constant and metabolic fluxes follow stoichiometric relationships. 
Given measured constraints the networks predict metabolic capabilities, internal 
fluxes and phenotypic behaviour.
Ten years ago the first genome-scale metabolic network was published (103). The 
network represented the metabolism of Haemophilus influenza (104) and since then 
the number of models has risen, with over 70 genome-scale networks currently 
available (105). This approach has been most frequently applied to the study of 
metabolism by Bernhard Palsson and his research group. Bernhard Palsson has 
published numerous reaction networks, including networks that represent the model 
organism Escherichia coli (E. coli). E. coli is one of the most important model 
organisms in biology, and the networks generated for E. coli K-12 have gained the
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most attention of the published networks. Several sequential networks have been 
generated (106-109) with each updated version expanding on the previous model 
based on novel genomic and biochemical knowledge. The networks are still in 
development with further expansion predicted to include increased characterisation 
of promiscuous enzymes, addition of protein synthesis, and comparison with a 
greater number of datasets (110).
1.5.1.1 Applications of genome scale reaction networks
Genome scale metabolic reaction networks are being increasingly used for a wide 
variety of applications. For example, reaction networks have been used in studies 
involving: the analysis of microbial phenotypes, metabolic engineering, analysis of 
metabolic network properties, the study of evolutionary processes and the analysis 
of microbial interactions within multispecies environments. Most commonly, 
networks are combined with high-throughput data such as microarray, protein 
expression, gene essentiality, metabolomic, flux or Biolog data (108, 111-125). 
This analysis enables whole-cell contextualisation of in vitro results, the identification 
of metabolic pathways that experience significant alterations under different 
conditions, and generates a greater understanding of the relationship between 
cellular pathways. Additionally, these analyses can predict suitable drug targets by 
assessing the robustness of metabolic pathways.
Model-driven biological discovery often follows the initial analysis of reaction 
networks; as the comparison between theoretical and in vitro datasets highlights 
areas of metabolism where current metabolic knowledge isn't reflected by 
experimental observations. These discrepancies enable the generation of metabolic 
hypotheses which could explain the inconsistent results. Hypothesis generation and 
subsequent metabolic discovery is a key feature of the iterative process of genome 
scale modelling and results in a cycle of in silico and in vitro experiments. This cycle 
identifies novel metabolic features and results in increasingly accurate reaction 
networks.
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1.5.1.2 Genome scale modelling of M. tuberculosis, M. bovis and
M. bovis BCG
The availability of annotated genome sequences, as well as the fact that metabolism 
is generally a well-studied system, emphasises the suitability of reaction networks to 
study the metabolism of mycobacteria. The first M. tuberculosis genome scale 
metabolic network (GSMN-TB) was created by Beste et al,, in 2007 (115) for the 
H37Rv strain and a second model (INJ661) was also published in 2007 (116). The 
iterative nature of genome modelling has led to further versions of iNJ661 (iNJ661m 
(126) and iNJ661v (126)) and a combined Metamerge (114) network which used 
both GSMN-TB and iNJ661 to create a network with a larger scope than either 
individual model.
As well as providing an invaluable tool for metabolic investigations, these networks 
also provide a reference for future metabolic reconstructions, such as for M. bovis 
and M. bovis BCG. Adaptation of the M. tuberculosis metabolic networks to 
represent M. bovis and M. bovis BCG metabolism is aided by the fact that 
genetically the three microorganisms are remarkably similar.
1.6 Overall objectives of this project
The aim of this research project is to gain a greater understanding of the metabolism 
and metabolic differences between M. tuberculosis, M. bovis and M. bovis BCG. 
This was achieved by: (1) creating reaction networks for M. bovis AF2122/97 
(GSMN-MB) and M. bovis BCG Pasteur (GSMN-BCG); (2) analysing in silico 
metabolic predictions generated by the M. tuberculosis H37Rv, M. bov/s AF2122/97 
and M. bovis BCG Pasteur GSMN reaction networks and comparing them to in vitro 
experimental data; (3) investigating key discrepancies between in silico predictions 
and in vitro results; (4) iterative development of the GSMN reaction networks.
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The GSMN-MB network visualised using Cytoscape (127)
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2.1 Introduction
Systems biology (128) is an interdisciplinary field that uses experimental and 
computational methods to build mathematical models of biological systems. In biology 
the properties of a dynamic system, such as cellular metabolism, are the result of 
complex interactions between its constituent parts and not easily deduced from 
descriptions of its individual components. Analysis and system-level understanding of 
metabolism requires the assistance of computing technology. Computational biology 
aims to develop and use efficient algorithms, data structures and visualisation and 
communication tools with the intention of creating computer simulations of biological 
processes. The simulations utilise known parameters to predict system behaviour and 
function. The application of computer modelling to study the metabolism of 
M. tuberculosis, M. bovis and M. bovis BCG has enormous potential to facilitate a 
greater understanding of the metabolic capabilities and differences between these 
mycobacteria; and is aided by the fact that metabolism is a well-studied system in 
M. tuberculosis. Computational methods have already begun to be applied to create 
metabolic models of M tuberculosis, both on a genome and pathway level (114-116, 
126, 129).
2.1.1 Metabolic reaction networks
Metabolic reaction networks analyse individual reactions and enzymes within the 
perspective of the entire system. The networks correlate genome with metabolism by 
utilising a reaction matrix constructed from the genome of a microorganism. Certain 
parameters of the network are known and computer methods can be employed to 
deduce the constraints of unknown components from these input values. This enables 
the analysis, interpretation and prediction of metabolic capabilities under defined 
conditions.
Modelling of metabolic systems can be divided into structural (time-invariant) and 
kinetic (time-dependant) categories. Most reaction networks, including genome scale 
metabolic reaction networks, are time-invariant and use constraint-based approaches 
due to problems with generating non-stoichiometric data, especially for the entire 
network.
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2.1.2 Constraint based modelling
Constraint based modelling provides a steady-state description of metabolic behaviour 
where metabolite concentrations are constant and fluxes obey stoichiometric 
relationships. The steady state assumption is that there is no change in metabolite pool 
sizes over time, as the sum of the fluxes producing each metabolite is equal to the 
fluxes consuming it. It is assumed that the system is in equilibrium and therefore it is 
possible to perform mass balance analysis over the network. Constraint based 
modelling can be regarded as a precondition for kinetic modelling.
The first step in constraint based metabolic modelling is to construct a stoichiometric 
matrix (A/) consisting of all known metabolites (M; rows) and reactions (Q; columns) 
within the metabolic system. Cellular reactions can be inferred from genome 
annotations which predict the genes, and therefore enzymes, operating within the 
organism. The matrix defines the consumption and production of metabolites with a 
negative or positive value respectively. The values within the matrix equate to the 
stoichiometry of the metabolites involved in each of their respective reactions and 
contain all the information required to model metabolism at steady state. Via 
construction of the reaction matrix pathway holes may be identified where enzymes 
appear missing from the annotated reaction sequence. Reconstruction of these 
pathways involves predicting the probable genes to fill these missing steps based on 
the recognised annotations. Once a reaction matrix is completed simulation can be 
carried out. Simulation is defined as the process of exhibiting information contained 
within the network (130).
2.1.2.1 Flux balance analysis
A popular and efficient constraint-based simulation method is FBA. In FBA the rate of 
metabolite conversion is constrained via known values, such as metabolite uptake and 
utilisation or production. FBA is based on the principle of mass conversion for each 
metabolite and the understanding that biochemical networks are subject to certain 
physiochemical limitations that constrain the possible behaviours of a system. Internal 
constraints include: stoichiometry, reversibility and the flux rate of reactions which are 
confined to upper (positive value; forward reaction) and lower (negative value; reverse 
reaction) bounds. Exchange fluxes dictate external constraints by determining the 
uptake or export of certain metabolites. Therefore, exchange fluxes define which
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metabolites are contained within the system and those that can enter and/or exit. The 
exchange fluxes enable the availability of metabolites to the network to be defined and 
uptake of metabolites can be used to mimic in vitro or in vivo conditions (input).
Once the capabilities of the network have been described and the environment in 
which the network is to operate has been determined, FBA requires a function to 
optimise (objective function). The objective function for genome scale metabolic 
networks is usually biomass production, as this is predominately thought to be what a 
microorganism wants to maximise. However, production of any metabolite may also be 
optimised.
By applying these constraints to the network a ‘closed solution space’ for an external 
environment and optimisation function is defined, within which all possible steady state 
solutions lie. The optimal solution is found by using linear programming to identify the 
most efficient pathway through the network in order to achieve the optimal solution for 
an objective function. By finding the optimal solution FBA calculates the flux through 
every required pathway in the network, yielding information on biochemical capabilities 
and limits, maximum yields and the identity of the pathways being utilised. FBA can 
also be used to perform gene or reaction knockout studies, in which genes or reactions 
are given a constraint value of 0, removing them from the network. These simulations 
establish the sensitivity of the network or particular fluxes to perturbations and identify 
potential drug targets.
2.1.2.2 Limitations of flux balance analysis
Although the application of FBA to metabolic networks is currently the most efficient 
and utilised modelling method for genome scale metabolic networks (108, 111-122, 
131-141)’ there are various limitations to this approach. For instance, structural 
modelling requires steady state conditions and does not incorporate enzyme kinetics, 
transcription, translation or metabolic regulation. Consequently, predictive capabilities 
are restricted to situations where these factors do not significantly influence reaction 
rates. In addition, FBA computes one unique flux distribution, not all the mathematically 
acceptable solutions that satisfy the objective function. Possible flux boundaries that 
satisfy the optimal solution are calculated by an extension of FBA, called flux variability 
analysis (FVA).
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2.1.3 Metabolic networks of M. tuberculosis
The first published mycobacterial metabolic model was published in 2005 by Raman et 
al (129) and focussed on a small subset of cellular reactions that represented the 
pathways involved in mycolic acid synthesis. The network consisted of 197 
metabolites, 219 reactions and 28 proteins. However, the network did not involve 
mycobacterial metabolism on a cellular scale and therefore could not elucidate its 
metabolic capabilities.
Two genome scale metabolic networks, GSMN-TB and iNJ661 (115, 116) were 
published in quick succession in 2007. GSMN-TB was published by Beste et a!., (115) 
and contained 739 metabolites, 849 reactions and 726 genes, whilst INJ661 (116) is a 
slightly larger network of 826 metabolites, 1027 reactions and 661 genes published by 
Jamshidi and Palsson. The INJ661 network underwent modification in 2010 by Fang et 
a!., (126) to create an improved and an in-vivo compatible model, both with 1,049 
reactions, 663 genes and 838 metabolites. The availability of different genome scale 
metabolic networks led to the creation of an algorithm (114) for semi-automatically 
combining two existing models into a single metabolic network. An M. tuberculosis 
reaction network combining GSMN-TB and iNJ661 (115, 116) was generated via the 
algorithm, and includes 1400 reactions, 917 genes and 1,017 metabolites (114).
2.1.4 Aims
Investigations into the metabolism of M. bovis and M. bovis BCG are relatively sparse 
as compared to M. tuberculosis. Although there have been targeted investigations into 
metabolism of bovine tuberculosis strains, currently only the metabolism of 
M. tuberculosis has been studied on a genome-wide scale. A systems biology 
approach using genome scale reaction networks provides very effective methods for 
studying metabolic pathways, capabilities and cell viability on a whole-cell level. 
Therefore, the first goal of this project was to construct genome scale reaction 
networks for M. bows AF2122/97 and M. bovis BCG Pasteur.
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2.2 Methods
2.2.1 Construction of M. bovis and M. bovis BCG reaction
networks
Due to their close evolutionary history the first M. tuberculosis genome scale metabolic 
network (GSMN-TB (115)) (Appendices 1 - 2)  created for the H37Rv strain formed the 
basis for modelling M. bovis AF2122/97 (GSMN-MB) (Appendices 3 - 4 )  and 
M. bows BCG Pasteur (GSMN-BCG) (Appendices 5 - 6). Genolist (142), KEGG (143) 
and the TB database (144, 145) were used to assign respective M. bovis and 
M. bovis BCG gene numbers to the genes present in GSMN-TB (115), and alter 
annotations which since the GSMN-TB (115) was published have been assigned with 
an alternative enzymatic function. Using data compiled by Genolist (142) any DNA 
mutations between M. tuberculosis, M. bovis and M. bovis BCG leading to changes in 
protein sequence were identified. Published scientific literature was used to investigate 
these genes and to identify metabolic differences not caused by DNA mutations within 
enzyme sequences. This information was used to alter the network to reflect M. bovis 
or M. bovis BCG metabolism (Appendix 7).
2.3 Results
2.3.1 Constructing the GSMN-MB and BCG reaction networks
The genome scale metabolic network of M. tuberculosis (GSMN-TB (115)) (Appendix
1) was used as a starting point for the reconstruction of the genome scale networks of 
M. bovis (Appendix 3) and M. bovis BCG (Appendix 5). Reactions were adapted to 
reflect M. bovis and M. bovis BCG reactions based on genome annotations, protein 
sequences and published biochemical data (4-6, 45, 51, 79, 80, 82, 83, 146-162). For 
orthologous genes GSMN-TB (115) gene assignments were changed to M. bovis and 
M. bovis BCG gene numbers, with each DNA sequence analysed for changes relative 
to M. tuberculosis. The analysis identified 228 and 204 genes with non-synonymous 
sequence differences in M. bovis and M. bovis BCG as compared to M. tuberculosis 
(Table 2-1). These genes catalysed approximately 30% of reactions within each 
network.
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Table 2-1: Number of M. bovis or M. bovis BCG genes within each category of non- 
synonymous mutation event, relative to their corresponding M. tuberculosis homolog.
Number of genes
Mutation event M. bovis M. bovis BCG
Amino acid substitutions 186 185
InDels 31 13
Frameshifts 11 5
Deleted genes 13 15
Each genetic change relative to M. tuberculosis was assessed for potential enzymatic 
significance and the constructed GSMN-MB and GSMN-BCG networks modified to 
reflect predicted functional changes (4-6, 45, 51, 79, 80, 82, 83, 146-163) (Appendix 7). 
In total 257 M. tuberculosis genes contained mutation events in either or both M. bovis 
and M. bovis BCG homologs, with published literature available for 129. This evidence 
was used to support the retention, removal or addition of enzymes and reactions. 
Without evidence of gene inactivation all remaining homologs with mutations as 
compared to M. tuberculosis were left in the GSMN-MB and BCG networks. Scientific 
literature was also used to identify loss of enzyme activity due to reasons other than 
DNA mutations within the gene of interest, e.g. inadequate gene expression levels. All 
identically sequenced genes and their catalysed reactions for which no published 
literature is available have been left as they are in the GSMN-TB (115), due to the 
assumption of similarity between these processes unless mutation events or in vitro 
evidence suggests otherwise.
Despite the relatively large number of mutational events identified, only a small 
proportion (-19%) of sequence differences were predicted to lead to metabolic 
differences requiring network modifications, the vast majority of which were the 
removal of genes and reactions (Table 2-2; Appendix 7). For GSMN-MB 42 genes and 
14 reactions were deleted from the original GSMN-TB network, whilst slightly fewer 
genes (40) and more reactions (16) were deleted from the GSMN-BCG. These 
alterations appear to support the theory that M. bovis has evolved from a progenitor of 
the M. tuberculosis complex and that M. tuberculosis is more closely related to this 
common ancestor (16).
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Table 2-2: Modifications to the GSMN-TB in order to create the GSMN-MB and BCG
numerical value Number of genes catalysing the reaction; 0 indicates reaction is deleted from
the network unless specified as an orphan reaction
=> Irreversible reaction
<=> Reversible reaction
Biomass Required for Biomass production
Gene GSMN-TB GSMN-MB GSMN-BCG
Glycerol kinase (glpK) 1 - 1
Glycerol-3-phosphate dehydrogenase (g/pD) 2 2 3
GDP-D-rhamnose biosynthesis {gca, gmdA) 2 1 1
GDP-4-dehydro-6-deoxy-D-mannose epimerase 1 0 0
UTP-hexose-1-phosphate uridylyltransferase (ga/7) 2 1 1
(3-glucosidase (bglS) 1 - -
Pyruvate kinase (pykA) 1 - 1
Isocitrate lyase (ici) 1 2 2
(S)-2-hydroxy-acid oxidase 1 - -
Nitrate reductase (nar) 5 - -
Fumarate reductase {frd) 8 7 7
Glycine dehydrogenase {gcvB) <=> = > = >
L-serine ammonia-lyase {sdaA) 1 1 -
Alanine dehydrogenase (aid) 1 - -
Nicotinamidase 1 - -
Precorrin-6Y C5,15-methyltransferase 1 - -
Molybdopterin biosynthesis protein (moaE) 3 - -
enoyl-CoA hydratase/isomerases (echA) 21 21 21
Phospholipases 28 23 23
Methoxy mycolic acid synthase {mmaA3) 1 1 -
Synthesis of methoxy mycolic acids Biomass Biomass
Polyketide synthase (pks15/1) - 1 1
Glycosyltransferases 2 - -
Sulfotransferases 3 2 3
Sulfolipid-1 synthesis 1 - -
Mas-like gene {msl3, msl4, msIS) 4 3 3
Nitrate transporter (narK2) 1 - -
Phosphate transport via ABC system 8 - -
Glycerol-3-phosphate antiporter (ugp) 4 - -
Sulfolipid 1 Biomass
Mycoside b Biomass Biomass
Triacylglycerol synthases 15 14 14
2.3.1.1 Identification of pathway holes
Construction of GSMN-MB and BCG identified a pathway hole in alanine biosynthesis. 
In M. tuberculosis, aid catalyses the interconversion of alanine and pyruvate, but this
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activity is lost (82, 83) in M. bovis and M. bovis BCG due to a frameshift caused by 
single base pair deletion (6). Deletion of aid from the bovine networks resulted in a 
non-feasible network (no growth) unless alanine was supplied as a substrate, since this 
is the only biosynthetic route leading to alanine in the network. Yet, in contrast to the 
predictions M. bovis and M. bovis BCG are not alanine auxotrophs. Alanine 
dehydrogenase knock-out mutants of M tuberculosis are also not alanine auxotrophs
(81) and ^^ C labelling experiments detected identical alanine labelling patterns (164) for 
M. tuberculosis and M. bovis BCG; indicating that an alternative pathway for alanine 
synthesis must be active in all three strains. To preserve alanine prototrophy, the aid 
reaction (R246) has therefore been retained in the GSMN-MB and BCG model as an 
irreversible orphan reaction (82). Investigations into possible alanine biosynthesis 
reactions are detailed in ‘4.3.2.2; Alanine metabolism’.
2.3.2 Iterative development of the GSMN-TB
The construction of GSMN-MB and BCG required the iterative development of 
GSMN-TB (115) to create an updated version, GSMN-TB 1.1 (Appendices 1 - 2). 
GSMN-TB 1.1 includes updated gene annotations (153, 159, 165) and reaction 
pathways (165), such as the addition of cholesterol metabolism which was not 
incorporated into the published version (115).
2.3.3 Characteristics of the GSMN-MB and BCG metabolic
networks
The constructed metabolic networks for both M. bovis and M. bovis BCG contain fewer 
reactions, metabolites and genes than the updated GSMN-TB (115) network, 
GSMN-TB 1.1 (Table 2-3). The figures relate to unique stoichiometric formulae 
because paralogous genes involved in the same reaction were accounted for by 
Boolean statements describing gene-protein associations as opposed to reaction 
duplication. All three GSMN networks are available in the Appendices 
(Appendices 1-6)  and online for use with our interactive software 
(http://sysbio.sbs.surrey.ac.uk/) (166).
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Table 2-3: Statistics of the GSMN reaction networks
Reaction Class
Reaction network
GSMN-TB 1.1 GSMN-MB GSMN-BCG
Total number of reactions 876 863 861
Cytosolic reactions 745 735 733
Transport reactions 131 128 128
Genes 759 718 720
Orphan reactions 198 200 200
Total number of metabolites 766 757 754
Internal metabolites 667 660 657
External metabolites 99 97 97
2.3.3.1 Pathway analysis of the GSMN networks
The metabolic pathways that constitute the GSMN networks involve a range of 
processes, with all three models having a similar percentage of their network covered 
by each pathway classification due to their genetic and metabolic similarity 
(Figure 2-1). Two thirds of the reactions within each network consist of four metabolic 
pathway groups: lipid biosynthesis, amino acid metabolism, transport reactions and 
cofactor biosynthesis. The high percentage of reactions and genes (-23% ) involved in 
lipid biosynthesis within the GSMN networks reflects the importance of lipid metabolism 
to mycobacteria and the wide array of lipids present in the cell wall (5, 167).
Figure 2-1: Network coverage of each reaction pathway in GSMN-MB.
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2.4 Discussion
The first genome scale metabolic models for M. bovis and M. bovis BCG have been 
developed as downloadable files and as interactive web tools, freely available for use 
by the other researchers. The networks incorporate nearly all known biochemical 
reactions and describe the biosynthetic pathways that lead to the synthesis of all major 
macromolecular components. Therefore, GSMN-MB and GSMN-BCG instantiate 
current knowledge on the metabolism of M. bovis and M. bovis BCG and provide an 
invaluable tool for the analysis and comparison of their metabolic pathways. Any 
identified differences have the potential to aid investigations into causes of 
M. bovis BCG attenuation and the suitability of novel vaccines. To our knowledge this 
is the first time the metabolism of a pathogen and its vaccine strain have been 
compared on a systems level.
Metabolic differences have traditionally been used as a diagnostic tool to distinguish 
M. tuberculosis from M. bovis, and these genetic distinctions were implemented in the 
GSMN networks. For instance, M. tuberculosis has both nitrate reductase (148-152, 
160) and (3-glucosidase activity (79, 156) whereas both M. bovis and M. bovis BCG do 
not (79, 148-152, 156, 160). However, the most prominent metabolic feature of 
M. bovis strains is a disconnect between glycolysis and the TCA cycle caused by an 
inactive pykA (6, 80, 81). This defect results in the inability of glycolytic intermediates to 
enter the TCA cycle (80, 81). Subsequently, traditional M. tuberculosis growth medium 
must be supplemented with alternative carbon sources, such as pyruvate or fatty acids, 
because neither glucose, nor glycerol, which is the favoured carbon source of 
M. tuberculosis in vitro, can be utilised for growth. Additional defects in glycerol 
metabolism differentiate the mycobacteria as M. bovis AF2122/97 possesses an 
inactive gIpK (6, 80) and glycerol-3-phosphate transporter (6). M. bovis BCG has also 
lost glycerol-3-phosphate transporter activity (4) and have an extra glycerol-3- 
phosphate dehydrogenase gene due to regions of duplication found in this species (4).
Other genetic differences in central metabolic pathways include enzymes involved in 
the TCA cycle, glyoxylate shunt and amino acid metabolism. The enzymes isocitrate 
lyase aceA (glyoxylate shunt) and the fumarate reductase/succinate dehydrogenase 
genes frdB and frdC (TCA cycle) are both affected by frameshifts in the human 
{M. tuberculosis H37Rv strain) and bovine tuberculosis strains respectively (4-6). 
However, due to gene redundancy M. tuberculosis H37Rv retains isocitrate lyase {ici) 
activity (168) and fumarate reductase/succinate dehydrogenase has also been
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detected in M. bovis and M. bovis BCG (169). Conversely, the defects in enzymes of 
amino acid metabolism do result in loss of activity and also the inability of bovine 
strains to utilise some amino acids, aid is inactivated in M. bovis and M. bovis BCG and 
results in the inability to catabolise alanine and the conversion of glyoxylate to glycine 
(6, 81-83). The removal of aid from the bovine networks created a pathway hole, 
whereby no reaction within the bovine networks was able to synthesise alanine. This is 
a finding investigated in ‘4.3.2.2: Alanine metabolism’. Additionally, M. bovis BCG 
Pasteur has lost sdaA activity and the ability to utilise serine as a sole nitrogen source
(82).
Another main difference between the M. tuberculosis, and M. bovis and M. bovis BCG 
reaction networks, is the altered Biomass composition due to the addition mycoside b 
{M. bovis and M. bovis BCG) (147) and the removal of sulfolipid 1 (SL-1) (M. bovis and 
M. bovis BCG) (161) and methoxymycolic acids (146) {M. bovis BCG only). The 
removal of genes involved in the synthesis of these and other cell wall lipids 
(phospholipases, polyketide synthases, g ly cosy I transferases, sulfotransferases, 
triacylglycerol synthases, mas-like genes and mmpL genes (6, 146, 147, 154, 155, 
157, 158, 161, 162)) comprise approximately a third of all bovine network alterations, 
with lipid synthesis the most common reaction pathway in which alterations were made.
The remaining modifications cover a variety of processes, such as transport, cofactor 
biosynthesis and carbon metabolism. A frequent cause of these metabolic defects are 
the RD, with RD4, RD9, RDI 2 and RDI 3 deleting GDP-4-dehydro-6-deoxy-D-mannose 
epimerase, precorrin-6Y C5,15-methyltransferase, (S)-2-hydroxy-acid oxidase and 
molybdopterin biosynthesis protein moaE (6, 45). Additionally, nicotinamidase, enoyl- 
CoA hydratase 1, the ABC phosphate transport system and narK nitrate transporter are 
inactivated in M. bovis and M. bovis BCG (4-6, 150-152, 163, 170) with enoyl-CoA 
hydratase 18 active, as compared to M. tuberculosis (4-6, 170).
The results above describe the construction of in silico models representing the 
metabolism of M. tuberculosis, M. bovis and M. bovis BCG. The reaction networks 
implement current knowledge on the genetic differences between the mycobacterial 
species and permit the establishment of defined in silico conditions for investigating the 
metabolic capabilities of these microorganisms. Through the interrogation of these 
models the aim is to characterise their metabolic capabilities and differences within the 
context of cellular metabolism and resultant phenotype.
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3.1 Introduction
Metabolic networks must be validated by comparing biochemical, physiological and 
growth characteristics in silico and in vitro, in order to determine how accurately the 
network characterises the system it represents. Commonly used data sets include: 
gene essentiality. Biolog phenotype microarray (Biolog PM) and growth rates. 
Inconsistencies between data sets indicate deficiencies within the model and can arise 
as a result of a number of issues, for example, incorrect or incomplete gene 
annotations and reaction pathways. The information gained from these comparisons 
can be used to generate new hypotheses and experiments that advance the 
understanding of metabolic processes and help to refine the network. An iterative cycle 
of simulation, experimental comparison and model refinement is often required before 
networks adequately represent metabolic systems and have a satisfactory predictive 
capability.
3.1.1 Prediction of growth phenotypes
A primary use of genome scale metabolic reaction networks is the prediction of growth 
phenotypes. Genome scale metabolic reaction networks include all processes 
necessary for biomass production and can therefore predict the metabolic 
requirements and capabilities of growth and energy generation. Growth phenotypes 
can be predicted either in a qualitative manner, such as the ability to grow on a 
substrate, or quantitatively (171) if biomass optimised, by determining growth rates.
3.1.1.1 Biolog Phenotype Microarray
Biolog PM (172) is a commercially available phenotype microarraying platform that is 
capable of high-throughput screening for the ability to utilise a large number of 
substrates. It employs the reduction of tétrazolium dye by NADH as a reporter system 
for measuring respiration and defining bacterial growth phenotypes. The technology 
consists of: 96 well plates, tétrazolium dye and an ‘Omnilog’ analytical instrument. 
Each well, minus a negative control, contains a different nutrient or condition. The 
plates designated PM1 through to PM4 analyse the metabolic capabilities of carbon, 
nitrogen, sulphur and phosphorous pathways, whilst the remaining plates (PM5 - 20) 
can be used to determine respiration in a range of conditions, such as varying pH or
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the presence of antibiotics. Therefore, each well is designed to test a different cellular 
property or pathway. Respiration of a cellular suspension on the substrate within the 
well produces NADH, reducing the tétrazolium dye. The ensuing change in opacity, 
and therefore the cellular response, is monitored over a specified period of time by the 
‘Omnilog’ instrument. From this data Omnilog provides quantitative and kinetic analysis 
of cellular respiration in each well.
Biolog PM has been used to qualitatively evaluate in silico substrate utilisation and the 
accuracy of metabolic pathways for numerous genome scale metabolic reaction 
networks (108, 111, 117, 118, 133, 136-141). However, this technology has not 
previously been used for comparison with mycobacterial reaction networks. Qualitative 
analysis of metabolite utilisation enables the evaluation of catabolic pathways included 
within the network. For instance, the inability to metabolise a viable in vitro substrate in 
silico may indicate an incomplete degradation pathway. Often these studies use Biolog 
with respect to bacterial growth; however, although generally associated with cellular 
growth, respiration can occur independently over short periods of time.
3.1.1.2 Growth rates
FBA analysis is able to quantitatively predict growth phenotypes (171) as it computes 
the maximal growth achievable by the network given the available external substrates. 
This analysis relies on the assumption that maximisation of biomass is the driving 
principle of metabolism (171). Although maximisation of biomass production in vitro 
may not always be achieved, this assumption has been supported by several genome 
scale reaction networks (108, 115, 116, 122, 132,134,171).
3.1.1.2.1 Predictive accuracy of growth rates by M. tuberculosis 
reaction networks
The validation of both GSMN-TB (115) and iNJ661 (116) included quantitative analysis 
of predicted growth rates. For GSMN-TB (115) in vitro data for M. bovis BCG growing 
at three growth rates in glycerol-limited continuous culture was compared against 
network predictions, with in silico biomass production within the 95% confidence 
interval of the experimental value. iNJ661 (116) also accurately represented growth
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rates, with predicted biomass production on three different media matching 
experimental data.
3.1.2 Gene essentiality predictions
Genome scale metabolic reaction networks are commonly used to predict the effect of 
gene deletions on growth phenotypes (108, 111-122). Each enzyme is associated to 
the reactions it catalyses by a Boolean rule which states that: genes encoding 
enzymatic subunits are linked with an ‘AND’ whilst genes encoding alternative 
enzymes are connected with an ‘OR’. The knock-out simulation of individual genes 
translates the reactions connected to each deleted gene into ‘blocked’ reactions with 
flux constraints of zero. FBA is then applied to predict the growth phenotypes of each 
gene knockout. Comparison of in silico and in vitro gene knockout data produces four 
categories of results: false negative predictions - growth was predicted yet not 
observed experimentally; false positive predictions - growth was not predicted yet 
observed experimentally; true negative predictions - growth was predicted and 
observed experimentally; true positive predictions - growth was not predicted and not 
observed experimentally. Inconsistencies between data sets may be caused by the 
limitations of constraint based modelling, or errors in the network. For instance, in vitro 
regulation that prevents the use of alternative pathways may cause false negative 
results, whilst false positive results may indicate biomass components are not actually 
essential or that substitute pathways are missing from the network.
3.1.2.1 in vitro gene essentiality predictions of M. tuberculosis
Two datasets exist for the identification of M. tuberculosis genes that are essential in 
vitro (173, 174). Both studies used a library of himarl based transposon insertion 
mutants (175) but employed different identification techniques in order to identify genes 
unable to sustain insertion events. The initial experiment (TraSH) used DNA 
microarray technology (174) but limitations were associated with this method, including 
the inability to generate data for all genes within the genome. The updated method 
used Illumina deep sequencing (173) and had 100% genome coverage.
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3.1.2.2 Predictive accuracy of gene essentiality by M. tuberculosis 
reaction networks
All genome scale metabolic reaction networks for M. tuberculosis have used gene 
essentiality predictions via TraSH analysis to evaluate the reaction networks, with 
varying degrees of success. GSMN-TB (115) and the MetaMerge model (114) predict 
the in vitro dataset with 78% and 73% accuracy respectively, whilst INJ661 (116) and 
iNJ661m (126) are less efficient at reproducing the TraSH data set with a calculated 
accuracy of -56%.
3.1.3 Aims
Metabolic reaction networks require validation through the comparison of in siiico and 
in vitro biochemical, physiological, and growth characteristics. These comparisons 
evaluate how closely the network predictions match published experimental data and 
whether the models replicate known metabolic features and differences. As such, the 
comparison of in siiico and in vitro datasets will also indicate where the models need 
refining and areas of metabolism which require further investigation. Therefore, the 
purpose of this study was to validate the GSMN reaction networks via analysis of 
substrate utilisation, gene essentiality and growth rates.
3.2 Methods
3.2.1 Bacterial strains and growth conditions
M. tuberculosis H37Rv, M. bovis AF2122/97 and M. bovis BCG Pasteur were used for 
this study. Frozen stocks were maintained in 10% (vol/vol) glycerol at -80°C. 
Middlebrook 7H9 broth containing 5% (vol/vol) albumin-dextrose-catalase enrichment 
medium supplement (ADC) (Becton Dickenson), 0.2% (w/vol) pyruvate and 0.05% 
(vol/vol) Tween 80 was used to statically grow cultures from frozen stocks at 37°C. 
Brain heart infusion agar was used to assess culture purity (Becton Dickinson).
For the Roisin’s agar experiments cultures were grown until late exponential phase 
(ODeoo = 1.0) in 7H9 containing ADC, pyruvate and Tween 80 (as described), washed 
twice with Ringer’s solution with 0.2% (vol/vol) tyloxapol and plated in triplicate onto 
Roisin’s agar containing sole carbon and nitrogen sources. When testing sole carbon
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source assimilation, cells were grown on Roisin’s minimal media (176) with 1% (w/vol) 
agarose and 0.5% (w/vol) (2-oxoglutarate, L-alanine, D-arabinose, L-arginine, L- 
asparagine, L-aspartic acid, citrate, D-fructose, fumarate, D-galactose, D-glucose, L- 
glutamate, L-glutamine, glycerol, glycine, L-histidine, L-isoleucine, D-lactose, L-leucine, 
L-lysine, malate, D-maltose, D-mannose, L-methionine, L-phenylalanine, L-proline, 
propanoate, pyruvate, D-raffinose, D-rhamnose, D-ribose, L-serine, D-serine, 
succinate, D-sucrose, L-threonine, D-trehalose, L-valine, D-xylose) or 0.2% (w/vol) 
(acetate) carbon source. When testing sole nitrogen source assimilation Roisin’s 
minimal media was used with 0.5% (w/vol) pyruvate, 1% (w/vol) agarose and 0.59% 
(w/vol) sole nitrogen source (L-alanine, ammonia, L-arginine, L-asparagine, L-aspartic 
acid, L-cysteine, L-glutamate, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, 
L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, D-serine, L-threonine, L- 
tryptophan, L-tyrosine, urea, L-valine). Plates were incubated for up to 12 weeks. To 
test for any mutations which may have given false results any positives after 6 weeks 
were independently tested a further two times.
3.2.2 Biolog phenotype experiments
Paul Wheeler (AHVLA) and Bhagwati Khatri (AHVLA) generated the Biolog data for 
analysis.
Biolog PM (172) experiments which examined the ability of M. tuberculosis H37Rv and 
M. bov/s AF2122/97 to respire in the presence of 190 carbon and 95 nitrogen sources 
(PM1, 2a, 3b (172)), were obtained from Khatri B. et ai., 2012 (177). Equivalent 
experiments for M. bovis BCG were carried out using the described method (177). 
Three to four biological replicates were performed for each plate and a cell free control 
plate was also included to test for abiotic dye reduction.
3.2.2.1 Data analysis
The raw data was analysed using OmniLog PM kinetic plot software (172), with final 
colour intensity values and manual analysis of kinetic curves used to assess 
respiration. Wells were considered positive if the final colour intensity value minus the 
negative control and minus the standard deviation of the negative controls was a 
positive value (117). Positive results were confirmed manually by viewing the kinetic
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curves (178). Substrates considered to be respired had at least 50% of wells showing 
a positive result. The confidence levels applied to the data were determined by the 
number of concordant results for each biological replicate (117). High, medium and low 
confidence results were categorised as substrates where 100%, >75% and >50% of 
replicates produced the same result.
3.2.3 Modelling of phenotype experiments
The composition of Biolog base media (172) is not published, however mycobacteria 
were not able to respire in this medium without the added carbon or nitrogen source. 
To model the carbon source experiment we therefore simulated the media as a 
modified form of Roisin’s minimal media (176) containing unlimited quantities of 
ammonia, phosphate, iron, sulphate, carbon dioxide and a Biolog carbon source influx 
of 1 mmol/g DWt/h. Similarly the nitrogen source experiment was simulated using a 
modified form of Roisin’s minimal media, where ammonia was replaced with 1 mmol/g 
DWt/h of the Biolog nitrogen source and pyruvate was used as a carbon source influx 
at 1 mmol/g DWt/h. Flux balance analysis (FBA) was performed under aerobic 
conditions and using biomass as the objective function.
3.2.4 Modelling of growth rate experiments
To model /n vitro growth rate experiments in GSMN-TB 1.1 and BCG we simulated the 
media as a modified form of Roisin’s minimal media (176) (3.2.3: Modelling of
phenotype experiments) with modifications to the amount of available carbon sources. 
Carbon source input was constrained to experimentally derived values (164) and FBA 
was performed under aerobic conditions using the biomass composition for slow or fast 
growth (115) as the objective function.
3.2.5 Gene essentiality predictions and comparison with TraSH
and deep sequencing data
Huihai Wu (University of Surrey) calculated p-values, generated ROC curves and 
distribution plots.
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The maximal theoretical growth rate of each in siiico gene knock out was calculated by 
removing single genes from the network and performing FBA linear programming. To 
model the experimental conditions used in the TraSH experiment (174) input fluxes 
were constrained to represent 7H10 agar composition under aerobic conditions (115) 
with carbon sources allowed to enter the network at a rate of 1 mmol/g DWt/h and all 
other substrates unlimited. The objective function was set to biomass. For each 
theoretical gene knock out, flux through reactions requiring that particular gene were 
constrained to 0. Genes were considered essential for growth if the resulting growth 
rate was less than an arbitrary threshold of 0.001 (h' )^ (115). These computational 
predictions were statistically compared to the gene essentiality findings of TraSH 
mutagenesis (174) and deep sequencing (173).
3.3 Results
3.3.1 Validation of the GSMN reaction networks by comparison
with phenotype data
Paul Wheeler (AHVLA) and Bhagwati Khatri (AHVLA) generated the Biolog data for 
analysis.
The Biolog (172) high throughput metabolomics system was utilised to obtain additional 
insight into metabolic capability of M. tubercuiosis, M. bovis and M. bovis BCG and as 
test of the predictive accuracy of the GSMN networks (Appendices 8-13). Biolog 
technology measures respiration which is different from growth, as predicted by the 
network models; but our working assumption was that some degree of growth has to 
occur to reduce the respiratory substrate sufficiently to see a positive reaction.
3.3.1.1 Carbon and nitrogen utilisation
Carbon substrate utilisation for M. tubercuiosis, M. bovis and M. bovis BCG is 
presented in Table 3-1 (showing only substrates metabolised by at least one strain). Of 
the 190 carbon sources tested (Appendices 8 -10)33  substrates were metabolised by 
at least one of the mycobacteria tested, with 17 utilised by all three. These substrates 
included amino acids, TCA cycle intermediates, sorbitan derivatives, 3 carbon 
compounds and hexose or hexose containing carbohydrates. M. tubercuiosis was able 
to respire more of these substrates (27) than M. bovis (25) or M. bovis BCG (22). Of
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the 95 nitrogen sources tested (Appendices 11 -13) only 13 were able to be utilised as 
sole nitrogen sources (Table 3-2) by at least one of the three strains, and of these 9 
were amino acids. Unlike carbon source data, the number of nitrogen sources utilised 
was similar between the three species. Overall, the majority of tested substrates 
(-89%) were classified as ‘high confidence’ where replicates produced identical 
outcomes.
Table 3-1: Carbon substrates able to be utilised by M. tuberculosis, M. bovis and M. bovis BCG
C utilised as a carbon substrate
not utilised as a carbon substrate 
NT not tested
M. tuberculosis H37Rv M. bovis AF2122/97 M. bovis BCG Pasteur
Biolog Roisin's in siiico Biolog Roisin's in siiico Biolog Roisin's in siiico
2-oxoglutarate C C C - c 0 - 0 C
Acetate 0 C C C c c 0 c 0
Acetoacetic acid C NT - 0 NT - c NT -
Adenosine - NT C - NT c c NT C
D-alanine C NT C - NT - - NT -
L-alanine 0 C C - - - - - -
L-asparagine C C C - c c 0 c c
Butyric acid C NT - C NT - c NT -
Caproic acid C NT C C NT c c NT c
Citrate C 0 0 C c c c c c
D-fructose-6-phosphate C NT 0 C NT c - NT c
D-glucose-6-ptiosptiate C NT c - NT c c NT c
D-glucose C 0 C C - c - c c
L-glutamate C C 0 0 c c 0 c c
L-glutamine C C 0 - c c - c c
Glycerol C 0 c C - - 0 0 c
Glycine C C C - c c - c c
L-lactate C NT 0 c NT c c NT c
D-malic acid - NT - c NT - c NT -
L-malic acid C C C c c 0 c c c
D-mannose - C C 0 c c - c c
Mettiyl-pyruvate C NT - c NT - 0 NT -
Mono-methyl-succinate C NT - c NT - c NT -
N-acetyl-glucosamine - NT - c NT - - NT -
Oxalomalic acid C NT - c NT - c NT -
Propanoate - C C c c c c C c
Pyruvate C C C 0 c c c C c
D-serine C - - c - - - - -
D-tagatose - NT - c NT - - NT -
D-trehalose C C C c c c 0 C c
Tween 20 C NT C c NT c 0 NT 0
Tween 40 C NT C 0 NT c c NT c
Jween 80 C C C c c .9: 0 C c
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Table 3-2: Nitrogen substrates able to be utilised by M. tuberculosis, M. bovis and 
M. bovis BCG.
N utilised as a nitrogen substrate 
not utilised as a nitrogen substrate 
NT not tested
M. tuberculosis H37Rv M. bows AF2122/97 M. bovis BCG Pasteur
Bioiog Roisin's in siiico Bioiog Roisin's in siiico Bioiog Roisin's in siiico
L-alanine N N N - - - - - -
Aliantoin - NT - N NT - - NT -
L-asparagine N N N N N N N N N
L-aspartic acid - N N - N N N N N
L-cysteine N - - N N - N - -
D-gaiactosamine N NT - N NT - N NT -
D-giucosamine - NT - N NT - - NT -
L-giutamic acid N N N N N N N N N
L-giutamine N N N N N N N N N
L-ornithine N NT - N NT - N NT -
D-serine N - - N - - N - -
L-serine N N N N N N - N N
L-threonine - N N - - N N - N
3.3.1.2 Accuracy of the GSMN networks at predicting Biolog data
Analysis of in siiico predictions verses Biolog data showed that all three networks 
qualitatively reproduced Biolog results with a similar overall accuracy. For 
GSMN-TB 1.1, GSMN-MB and GSMN-BCG in siiico simulations matched 84%, 81% 
and 84% of Biolog substrate results respectively (Appendices 8 - 13). Of the 190 
carbon and 95 nitrogen sources these percentages relate to the incorrect predictions of 
28, 36 and 31 carbon sources and 17, 18 and 15 nitrogen sources by GSMN-TB 1.1, 
GSMN-MB and GSMN-BCG. The majority of incorrect results were Biolog negative but 
in siiico positive; indicating that the networks include metabolic pathways theoretically 
able to metabolise substrates that were not respired under the experimental conditions 
tested.
Substrate analysis identified a few results that appeared anomalous with previous 
studies (80-82, 179). For instance, M. bovis tested positive for glucose and glycerol 
respiration, although, as mentioned in ‘1.4.1: Metabolic differences’, M  bovis is unable 
to utilise carbohydrates including glucose and glycerol as sole carbon sources’ 
Similarly, many in siiico predictions for amino acid utilisation did not correlate with 
Biolog and experimental data (82, 179).
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3.3.1.3 Accuracy of the GSMN networks at predicting combined 
phenotype data
To independently probe the discordant Bioiog and in siiico results M. tuberculosis, 
M. bovis and M. bovis BCG were grown on minimal Roisin’s agar media containing 
sole carbon or nitrogen sources. These experiments assess biomass production rather 
than respiration and may thereby more accurately test in slllco predictions of growth 
than Bioiog.
Overall, these experiments resolved many of the inconsistencies between In slllco 
predications and the Bioiog data (Appendices 8-13). In accordance with expectations 
M. bovis was unable to grow on either glucose or glycerol when provided as the sole 
carbon source in Roisin’s agar. It has been shown previously (177, 180), and 
confirmed here (4.3.1: Analysis of glucose metabolism) that Tween 80 (present in the 
Bioiog wells) and glucose are used synergistically for growth by M. bovis strains. Many 
discrepancies in amino acid utilisation were also resolved for M. tuberculosis. 
However, for M. bovis and M. bovis BCG a higher number of amino acid results 
remained inconsistent with in siiico predictions, indicating a loss of substrate utilisation 
capability as compared to M. tuberculosis that was not represented in siiico. The 
differences in amino acid metabolism between M. tuberculosis, M. bovis and 
M. bovis BCG are discussed in ‘4.3.2: Analysis of amino acid metabolism’.
When the anomalous Bioiog results were corrected using the Roisin’s agar data the 
GSMN-MB model accurately predicts 87% of phenotypes studied, whilst the 
GSMN-BCG predicts 88% correctly. The GSMN-TB 1.1 is more accurate (91%) at 
simulating cellular phenotypes than the bovine networks due to a greater number of 
false positive growth predictions for M. bovis and M. bovis BCG.
3.3.2 Substrate uptake and corresponding growth rates
The GSMN-BCG was used to predict cellular growth rates in Roisin’s media using 
published experimental data (164) on substrate uptake rates and corresponding growth 
rates. Overall, in siiico predictions were similar to the experimentally determined 
growth rates (Table 3-3) and the growth rate generated by the GSMN-TB 1.1 network. 
Due to the inability of M. bovis to utilise glycerol, GSMN-MB was not tested.
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Table 3-3: Comparison of in siiico and in vitro growth rates on Roisin’s minimal media using 
calculated substrate uptake rates.
M. bovis BCG M. tuberculosis
Specific consumption rate 
(mmol g biomass’’' h’ )^
in vitro growth 
rate (h’ )^
in siiico growth 
rate (h’ )^
In siiico growth 
rate (h’’')
Glycerol 0.390 0.010 0.009 0.010Tween 80 0.002
Glycerol 0.740 0.030 0.030 0.030Tween 80 0.090
3.3.3 Validation of the models by comparison with global
mutagenesis data
In order to evaluate robustness, the impact of single gene deletions on the GSMN 
networks was analysed. In vitro experimental conditions (174) were simulated by 
allowing external compounds present in Middlebrook 7H10 media to enter the networks 
under aerobic conditions (115) and qualitative, theoretical growth rates were calculated 
for each in siiico gene knock out. An arbitrary threshold of 0.001 (h' )^ was employed to 
distinguish between essential and non-essential genes, with growth rates below 0.001 
(h' )^ indicative of an essential gene (115). All genes regarded as essential were lethal 
knockouts and had an in siiico growth rate of zero.
3.3.3.1 Gene essentiality in GSMN-TB, MB and BCG
Overall, calculations of gene essentiality within the GSMN-TB 1.1, MB and BCG 
reaction networks generate very similar results. However, GSMN-MB and BCG have a 
slightly higher percentage of essential genes (31% and 30% respectively; Appendices 
14 - 15) as compared to GSMN-TB 1.1 (29%; Appendix 16) due to the loss of non- 
essential genes during their evolutionary history. These values are slightly lower than 
the predicted value of 35% essential genes in the entire M. tuberculosis genome (181), 
but within the 95% confidence interval (28 - 41%).
Chapter 3: Validating the GSMN reaction networks 43
S.3.3.2 Accuracy of the GSMN networks at predicting global 
mutagenesis data
Huihai Wu (University of Surrey) calculated the p-values
In slllco gene essentiality predictions were compared with in vitro gene essentiality data 
as determined by transposon site hybridization (TraSH) mutagenesis (174) and 
deep-sequencing (173) (Appendices 14 -16). All models gave a very similar predictive 
accuracy (76 - 77%; Table 3-4) when compared against TraSH data, however, results 
were only available for 82% of genes in the models. Comparison of predictions with a 
more comprehensive evaluation (100% network coverage) of gene essentiality by 
deep-sequencing also generated a similar predictive accuracy (75%) for all three 
networks (Appendices 14-16).
Table 3-4: Analysis of gene essentiality predictions
Percentage of in siiico gene essentiality predictions categorised as:
True-positive: essential both in the model and experiment 
False-positive: essential in the model, nonessential in experiment 
True-negative: nonessential in the model and experiment.
False-negative: nonessential in the model, essential in experiment.
GSMN-TB 1.1 GSMN-MB GSMN-BCG
TraSH Deepsequencing TraSH
Deep
sequencing TraSH
Deep
sequencing
True positive 23% 23% 24% 24% 24% 24%
False positive 8% 6% 8% 6% 8% 6%
False negative 16% 19% 16% 19% 16% 20%
True negative 53% 52% 51% 50% 51% 50%
Correct
predictions 77% 75% 76% 75% 76% 75%
p value 0.005 0.955 0.011 0.687 0.008 0.863
3.3.3.3 Receiver operating characteristic curves
Huihai Wu (University of Surrey) generated the ROC curves
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Designation of a gene as either essential or non-essential is a binary characteristic that 
is generated from a continuous measurement of growth rate or mutant abundance 
(determined by microarray or sequencing) by applying an arbitrary cut-off value. To 
examine the influence of the cut-off value on predictive accuracy we plotted Receiver 
Operating Characteristic (ROC) curves (Figure 3-1; Appendices 1 7 -2 1 ). The majority 
(-91% ) of in siiico mutants generated a predicted growth rate equal to the wild-type or 
zero, so variation in the in siiico growth rate threshold had very little influence on the 
result. However, in vitro cut-offs did influence prediction accuracy so ROC curves were 
used to identify optimal values for the cut-off value of the measurement signal. For 
both TraSH and deep sequencing data sets the optimal micro array and p-value cut-offs 
were the original values of 0.2 and 0.05 respectively.
Figure 3-1 ; The GSMN-MB ROC curve for TraSH thresholds
The plot shows ROC curves for different transposon site hybridization (TraSH) ratio thresholds 
for determination of essential genes in experimental data. Five ROCs are plotted with 4 different 
TraSH thresholds as shown in the legend box. Each ROC curve shows the points 
corresponding to true positive rate (sensitivity) and false positive rate (1-specificity) of the model 
predictions obtained for all growth rate thresholds.
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3.3.5.4 Distribution plots
Huihai Wu (University of Surrey) generated the distribution plots
Due to the influence of in vitro cut-offs and as a further method of validating the 
networks predictive power, the distributions of the hybridization ratio of the TraSH 
library to genomic DMA signal was plotted for both essential and non-essential genes in 
siiico (growth rate threshold of 0.001) (Figure 3-2; Appendix 22-23). Additionally, 
similar graphs were plotted for the distributions of the p-value of the transposon library 
to genomic DNA signal for essential and non-essential genes in siiico (growth rate 
threshold of 0.001) (Appendix 24-26). For all GSMNs and in vitro methods of 
determining essential genes the medians of the two distributions were significantly 
different by means of the Mann-Whitney test (P < 2.2 x 10'^ ®). Therefore, compared to 
the original TraSH data genes considered essential in siiico have a significantly lower 
median value of insertion probe to genomic probe ratio than predicted non-essential 
genes. This is in agreement with TraSH data because a low ratio indicates that 
inactivation of the target gene by transposon insert results in depletion of the mutant 
strain after the growth on Middlebrook 7H10 medium. With regards to the deep 
sequencing method of essential gene identification, genes considered essential in siiico 
have a significantly lower median p-value than predicted non-essential genes. This 
agrees with the results of deep sequencing as a low p-value correlates to genes with 
few insertions relative to the numbers of TA sites within the gene sequence. Overall, 
this analysis demonstrates the predictive power of the networks using an approach that 
is independent of the cut-offs applied to the in vitro datasets.
3.3.3.5 Pathway analysis
Examining different areas of metabolism, the predictive accuracy (using deep 
sequencing data) varied from 61 -  62% in COM (glycolysis, TCA cycle, pentose 
phosphate cycle, methylcitrate cycle and anaplerotic reactions) to 95 - 96% in 
(3-oxidation of fatty acids (Table 3-5). The chief source of errors for central carbon 
metabolism genes were false-negatives: genes predicted to be non-essential in siiico 
but experimentally found to be essential. This likely reflects the multiple alternative 
pathways available for flux in siiico central metabolism, many of which are likely to be 
incapable of supporting sufficient flux for growth in real organisms. Peripheral areas of
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the network tend to generate higher predictive accuracies as fewer alternative 
pathways are available.
Figure 3-2: Distribution of the hybridization ratio of the TraSH library to genomic DNA signal 
recorded in TraSH experiment for genes present in the GSMN-MB.
The blue line shows the distribution of TraSH ratio among the genes that were predicted as 
essential for growth by the metabolic networks. The red line shows the distribution of TraSH 
ratio among genes predicted to be nonessential. The growth rate threshold is set as 0.001.
■  Predicted to grow
■  Predicted not to grow
§
2 0 2-4
log (TraSH ratio)
Table 3-5: Accuracy of gene essentiality predictions for each reaction pathway within the 
network
Pathway GSMN-TB 1.1 GSMN-MB GSMN-BCG
Amino acid metabolism 76 75 75
Carbohydrate metabolism (excl. CCM) 72 75 71
Cell wall synthesis 88 88 88
Central carbon metabolism 61 62 61
Cofactor biosynthesis 66 66 66
Lipid biosynthesis 77 77 78
Nucleotide biosynthesis 70 66 66
Other functions 65 63 63
Transport reactions 94 95 95
(3 oxidation of fatty acids 95 96 96
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3.4 Discussion
In siiico models are essentially a mathematical instantiation of current knowledge. 
Interrogating the models to generate predictions that can be tested against 
experimental datasets is thereby an efficient means of assessing predictive accuracy. 
The study described here illustrates this approach with the GSMN reaction networks 
representing the metabolism of M. tuberculosis, M. bovis and M  bovis BCG 
undergoing comparison with in vitro growth rates, substrate utilisation and gene 
essentiality. The in siiico experiments utilised a constraint-based FBA simulation 
approach which is currently the most practical method by which metabolic flux can be 
analysed in genome scale metabolic networks. This technique enables quantitative 
growth rates to be determined (171) for the chosen objective function (in this case 
biomass) and nutrient uptake conditions. Using this method all three networks 
demonstrated a high degree of predictive accuracy when reproducing in vitro growth 
rates, substrate utilisation and gene essentiality, thus confirming that the reaction 
networks accurately represent current metabolic theories.
Although the models efficiently reproduce in vitro datasets, these analyses are also an 
effective means of identifying metabolic inconsistencies and the limitations of current 
knowledge. For example, although the high-level of correlation between in vitro and in 
siiico gene essentiality data was shown to be independent of the cut-offs applied to the 
data, investigations into specific reaction pathways revealed that all three networks 
predicted a high level of pathway redundancy, especially in central pathways, such as 
carbon metabolism. This redundancy resulted in a greater percentage (83%) of non- 
essential genes within in siiico pathways than were found experimentally (50%), and is 
the cause of the almost identical results generated by all three networks. Pathway 
redundancy also results in GSMN-MB predicting the growth of M. bovis on glucose. 
This is contrary to expectations as this inability is a distinguishing feature of M. bovis 
strain of the tubercle bacillus. Presumably, the pathways utilised in siiico to connect 
between glycolysis and the TCA cycle are not able to support growth in vitro and 
additional unknown metabolic defects are also contributing to this phenotype (80). 
Although as shown specifically for the M. bovis glucose example, many of the 
alternative pathways available for flux in siiico are likely to be incapable of sufficient flux 
for growth in real organisms, the reported genome plasticity within these pathways (71, 
102, 164, 165) means further constraints on the reactions available to the networks, 
which would reduce pathway redundancy, cannot be applied with confidence.
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Further discrepancies identified between the models and in vitro data predominantly 
involve the metabolism of amino acids. For instance, alanine metabolism was identified 
as an area in which our knowledge of reaction pathways did not match in siiico 
predictions. Simulations indicated that an unknown reaction generates alanine in 
M. bovis and M. bovis BCG, as without the inactive alanine dehydrogenase enzyme 
alanine was unable to be synthesised by these microorganisms in siiico. Additionally, 
the in siiico models predicted very few metabolic differences between M. tuberculosis, 
M. bovis  and M. bovis BCG. Yet substrate utilisation capabilities between the strains 
decreased from M. tuberculosis > M. bovis > M. bovis BCG, with the most noticeable 
decrease involving amino acids. It seems that during their evolutionary passage from 
their common ancestor (that is presumed to be close to M. tuberculosis (16)), M. bovis 
and M. bovis BCG have lost some of their capability to metabolise compounds. In the 
majority of instances the basis of this loss in metabolic versatility is unexplained by 
current enzymatic knowledge.
Genome scale networks are continually developed as more metabolic information 
becomes available. As well as the incorporation of novel published data, information 
generated from the analysis of the GSMN networks can lead to network alterations. For 
instance, the use of in vitro data sets to validate the GSMN models has not only 
enabled the predictive accuracy of the reaction networks to be determined, but also 
identified metabolic pathways (glucose and amino acid metabolism) that require further 
investigation. The information generated from these investigations may be fed back 
into the network development process to continue the cycle of pathway development. 
The GSMN networks have been shown to successfully simulate many aspects of 
mycobacterial growth and metabolism, but through the continual improvement of their 
reaction pathways it is expected that the networks will gradually become more 
representative of metabolism over time.
Chapter 4: Investigating metabolic 
discrepancies
Mfadhlim
Central carbon metabolism in M. tuberculosis visualised using Cytoscape (127)
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4.1 Introduction
Hypothesis generation is a key part of genome scale modelling and the iterative nature 
of systems biology. Metabolic networks represent current metabolic knowledge and 
therefore in siiico predictions characterise the theoretical phenotypes achievable by the 
identified reaction network. Through the process of network validation differences 
between in siiico predictions and observed characteristics are identified, with the 
discrepancies highlighting areas of metabolism where our knowledge is incomplete. In 
order to determine why the disagreements arise, the metabolic pathways that when 
probed in siiico do not reproduce in vitro results, require further investigation. 
Hypotheses which could explain why the datasets disagree are then generated from 
analysis of the differences between in siiico and in vitro data and tested experimentally. 
The targeted investigations have the potential to further metabolic knowledge by 
revealing novel metabolic features and can aid in resolving errors within the reaction 
network. Therefore, investigation of metabolic pathways which do not accurately 
reproduce in vitro data in siiico, have the potential to further our understanding of 
metabolism and generate more accurate models from which a further cycle of 
model-driven hypothesis generation can be undertaken.
4.1.1 Aims
GSMN-MB and BCG networks gave similar predictions to GSMN-TB 1.1, but some 
interesting differences between in siiico predictions and published experimental data 
were found. GSMN-MB was able to utilise carbohydrates such as glucose in siiico 
although in vitro M. bovis is actually unable to grow on these substrates (6, 74, 80, 81), 
and in siiico amino acid phenotype predictions did not correlate with Bioiog and 
experimental data (81, 82, 179). Therefore, the purpose of this study was to investigate 
glucose and amino acid metabolism further.
4.2 Methods
4.2.1 Bacterial strains and growth conditions
M. tuberculosis H37Rv, M. bovis AF2122/97 and M. bovis BCG Pasteur were used for 
this study. Frozen stocks were maintained in 10% (vol/vol) glycerol at -80“C. 
Middlebrook 7H9 broth containing 5% (vol/vol) ADC enrichment medium supplement
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(Becton Dickenson), 0.2 (w/vol) pyruvate or 0.2% (vol/vol) glycerol, and 0.05% (vol/vol) 
Tween 80 or Roisin’s minimal media (176) with 0.5% (w/vol) pyruvate, 0.5% (w/vol) 
glucose or 0.5% (vol/vol) glycerol and 0.2% (vol/vol) tyloxapol or 0.2% (vol/vol) 
Tween 80 were used to grow cultures from frozen stocks at 37°C, either statically or 
rolling. Brain heart infusion agar was used to assess culture purity (Becton Dickinson).
For growth curves inoculum cultures of M. bovis and M. bovis BCG were grown 
statically until late exponential phase (ODeoo = 1.0) in Roisin’s minimal media (176) with 
pyruvate and tyloxapol (as described). Using a 1% inoculum 100 ml rolling cultures 
were set up in Roisin’s minimal media with 0.5% (w/vol) D-glucose, 0.2% (vol/vol) 
Tween 80 or 0.5% (w/vol) D-glucose and 0.2% (vol/vol) Tween 80 as carbon sources. 
A Biomate ThermoSpectronic spectrophotometer was used to take daily OD readings 
until they started to fall, presumably due to bacterial death.
4.2.2 Bioiog phenotype experiments
Refer to 3.2.2: Bioiog phenotype experiments
4.2.3 Roisin’s agar experiments
Refer to 3.2.1 : Bacterial strains and growth conditions
4.2.4 Modelling of phenotype experiments
Refer to 3.2.3: Modelling of phenotype experiments
4.2.5 Radioactive giucose uptake in M. tuberculosis H37Rv and 
M. bov/s AF2122/97
Cultures of M. tuberculosis and M. bovis were grown statically until late exponential 
phase (ODeoo = 1.0) in Roisin’s minimal media with pyruvate and tyloxapol (as 
described). Using a 1% inoculum 100 ml rolling (2 rpm) cultures were grown in the 
same media to ODeoo 0.6 -  0.8, washed twice and then resuspended in Roisin’s media 
(no carbon, tyloxapol).
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4.2.5.1 [6-^ "^ C] D-glucose incubation
1 ml of culture was added to a universal tube containing 0.1 pCi of [G-^ '^ C] D-glucose 
dissolved in 25 pi MilliQ water and 1 ml of 1 M sodium hydroxide. Negative controls 
were tested in parallel using identically prepared heat killed suspensions (90°C for 1 hr) 
of bacteria. Triplicate samples were incubated for 4 hr at 37”C
For the analysis of [6-^ "^ C] D-glucose radioactivity incorporation in M. bovis (when both 
[G-^ '^ C] D-glucose and non-radiolabelled Tween 80 were available as carbon sources), 
the experiment carried out as described above, except that the incubation medium was 
supplemented with 0.2% (vol/vol) Tween 80.
4.2.5.2 Sample preparation and analysis
Cultures were filtered through Whatman GFC glass microfibre filters and washed 3
times with 0.025% (vol/vol) tyloxapol. Filters were placed in scintillation tubes with 
250 pi of 70% ethanol and 5 ml of BDH Scintran Fluoran flow scintillation fluid. The 
1 ml samples of 1 M sodium hydroxide were directly added to 5 ml of scintillation fluid. 
Radioactivity was counted using a Packman tri-carb liquid scintillation counter and dpm 
calculated from a quench curve. Dpm for negative controls were subtracted from dpm 
for the live samples before the mean average uptake was calculated.
4.2.6 Investigations into alanine synthesis
4.2.6.1 Liquid chromatography-mass spectrometry (LC-MS) analysis
for the detection of aspartate-p-decarboxylase activity
Paul Wheeler (AHVLA) designed the sample preparation method and grew the cells. 
Lysate preparation, lysate incubation, PTC derivatisation and HPLC preparation was 
carried out together with equal participation.
Janine Gielbert (AHVLA) and Paul Wheeler designed the LC-MS method.
LC-MS sample analysis was carried out jointly with Janine Gielbert
Cultures of M. tuberculosis, M. bovis and M. bovis BCG were grown statically until late 
exponential phase (ODeoo = 10) in Middlebrook 7H9 containing ADC, pyruvate and 
Tween 80 (as described). Using a 1% inoculum 100 ml rolling (2 rpm) cultures were set
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up in Roisin’s minimal media with pyruvate and Tween 80 (as described) and once log 
phase (ODeoo 0.4 - 0.8) was reached, cells were harvested for lysate preparation.
4.2.G.2 Sample preparation
Cells were washed twice with 0.01 % (vol/vol) Tween 80 before pellet resuspension in a 
buffer containing 0.1 M potassium phosphate pH 7.5, 10 pg/ml leupeptin, 15 pM 
2-mercaptoethanol and 45 pM pyridoxal phosphate (182, 183). Cells were lysed at 6.5 
ms’”' for 20 s using Lysing Matrix B tubes and the FastPrep Sample Preparation 
System. Samples were desalted through a P10 Desalting Column (GE Healthcare) 
according to the manufacturer’s instructions. 50 pi of each cell extract was incubated in 
a water bath at 37°C with either: 25 mM aspartate; 25 mM aspartate and 1 mM a- 
ketoglutarate; 25 mM aspartate and 1 mM pyruvate; 1 mM aspartate; 1 mM aspartate 
and 1 mM a-ketoglutarate; 1 mM aspartate and 1 mM pyruvate; 25 mM ammonia and 1 
mM pyruvate. The final assay volume was 100 pi and the buffer contained: 0.1 M 
potassium phosphate pH 7.5, 10 pg/ml leupeptin, 15 pM 2-mercaptoethanol and 45 pM 
pyridoxal phosphate (182, 183). Some samples were set up in duplicate. At 0 min, 5 
min and 50 min, 100 pi ethanol was added to one of the samples for each culture with 
either 12 pi of 10 mM methanesulphonic acid (0 min and 5 min) or 12 pi of 1.25 M 
methanesulphonic acid (50 min). Control samples consisted of: 50 pi cell extract; 25 
mM aspartate; 25 mM aspartate and 1 mM pyruvate; 1 mM aspartate; 1 mM 
aspartate, 1 mM a-ketoglutarate and 1 mM pyruvate. Controls had 12 pi of 1.25 M 
methanesulphonic acid and 100 pi ethanol added to them at 50 min. All samples and 
standards went through the standard phenylthiocarbamyl (PTC) derivatisation 
procedure (183, 184). After PTC-derivatisation 200 pi of 14 mM ammonium acetate pH
6.4 was added to each sample before the samples were vortexed, pelleted and diluted 
1/100 with 14 mM ammonium acetate pH 6.4. 100 pi of each sample was added to 
HPLC vials.
4.2.6.S Liquid chromatography-mass spectrometry method
Mass spectrometry work was carried out using an Agilent Triple Quad LC/MS, set up 
with Agilent 1200LC modules, HPLC-chip cube, and using Electrospray Ionisation. 
Attached modules were Micro Wellplate Sample (model G137A7), NanoPump (model 
G2226A) and CapiliaryPump (model G1376A). Agilent MassHunter Workstation
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software (Data Acquisition, Qualitative Analysis and Quantitative Analysis) was used to 
operate the machine and analyse the resulting data. The solvents used were 0.1% 
formic acid (solvent A) and 90% acetonitrile, 10% water, 0.1% formic acid (solvent B). 
The solvent gradient was: 0 min, 70% A; 1 min, 70% A; 4 min, 40% A; 5 min, 0% A; 
7 min, 0% A; 8 min, 70% A and the flow rate was 4 pl/min. Standards of alanine 
underwent an MS scan set to an m/z range of 100 - 300, a product ion scan using 
different collision energies (20 V, 15 V, 10 V and 5 V) and MRM scans to enable 
sample detection, instrument optimisation and calibration.
4.2.G.4 Adjustments to the sample preparation method
Experimental repeats using M. bovis BCG were carried out as above with the following 
changes.
5 pi or 2 pi of cell lysate were used in the incubation procedure with samples taken at 
0 min, 1 min, 2 min, 5 min and 50 min. The enzyme inactivation procedure used either 
12 pi of 1.25 M methanesulphonic acid and 100 pi ethanol (5 pi and 2 pi cell lysate 
samples) or 12 pi of 1.25 M methanesulphonic acid and 200 pi ethanol heated in a 
heating block set to 80°C (5 pi cell lysate samples). Control samples were carried out 
as above using heat killed cell lysates.
4.2.7 Colourmetric assays for the detection of alanine synthesis
M. bovis BCG was grown statically until late exponential phase (ODeoo = 1) in 
Middlebrook 7H9 with ADC, glycerol and Tween 80 (as described). Using a 1% 
inoculum 100 ml rolling cultures (2 rpm) were set up in Roisin’s minimal media with 
glycerol and Tween 80 (as described) and cell growth was monitored daily at 600nm 
using a Biomate ThermoSpectronic spectrophotometer. Once log phase 
(ODeoo = 0.6 - 0.8) was reached, cells were harvested for lysate preparation. Cells were 
centrifuged twice at 4800 rpm for 10 min and resuspended in 0.01% Tween 80. 
Following centrifugation at 4800 rpm for 10 min cells were resuspended in 50 mM 
Hepes pH 7.0. Cells were lysed at 6.5 ms"'' for 20 s using Lysing matrix B tubes and the 
FastPrep sample preparation system. Protein estimations were carried out using the 
bicinchoninic acid assay (BCA) method with the BCA protein assay kit (Pierce)
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according to the manufacturer’s instructions. A standard plot was obtained to estimate 
the protein concentration (mg/ml) in each sample.
4.2.7.1 L-amino acid oxidase assay (adapted from Fusee et al. 1984 
(185)) for the detection of aspartate-P-decarboxylase activity
Reaction mixtures for determining specific activity contained: 100 mM potassium 
phosphate pH 7.5, 15 pM 2-mercaptoethanol, 45 pM pyridoxal phosphate, 25 mM 
aspartic acid, 1 mM a-ketoglutarate, 1 mM pyruvate, 0.5 U of L-amino acid oxidase, 
0.37 mg of 4-aminoantipyrine, 0.1 mg of 2,4-dichlorophenol, 0.8 U of horseradish 
peroxidase and with the volume of cell lysate varying between 1 and 200 pi in a final 
volume of 1 ml. Addition of aspartate initiated the reaction with the oxidative coupling of 
aminoantipyrine with 2,4-dichlorophenol registered at 505 nm.
4.2.7.2 Coupled alanine dehydrogenase assay for the detection of 
aspartate-P-decarboxylase activity
Reaction mixtures for determining specific activity contained 100 mM potassium 
phosphate (pH 7.5), 45 pM pyridoxal phosphate, 25 mM aspartic acid, 1 mM 
a-ketoglutarate, 10 pM phenazine methosulphate, 0.6 mM p-iodonitotetrazolium violet, 
10 U alanine dehydrogense, 0.3 mM nicotinamide adenine dinucleotide (NAD) and with 
the volume of cell lysate varying between 1 and 200 pi in a final volume of 1 ml. 
Addition of aspartate initiated the reaction with the reduction of p-iodonitotetrazolium 
violet registered at 505nm.
4.2.7.S Analysis of alanine transaminase activity (adapted from 
Yoneyama et al, 2011 (186))
Reaction mixtures for determining specific activity contained: 100 mM potassium 
phosphate (pH 7.4) or 100 mM tris (hydroxymethyl)aminomethane buffer (pH 7.4), 
20 mM a-ketoglutarate, 20 mM alanine, 0.2 mM reduced nicotinamide adenine 
dinucleotide (NADH), 45 pM pyridoxal phosphate, 5 U lactate dehydrogenase and with 
the volume of cell lysate varying between 1 and 200 pi in a final volume of 1 ml. 
Addition of alanine initiated the reaction with the oxidation of NADH registered at 
340nm.
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4.3 Results
4.3.1 Analysis of glucose metabolism
GSMN-MB incorrectly predicts that M. bovis should grow using glucose as a sole 
carbon source. In siiico, glucose enters central metabolism of M bovis via the glycolytic 
pathway and bypasses the blocked pykA  connection between glycolysis and the TCA 
cycle via either the anaplerotic/gluconeogenic enzyme, phosphoenolpyruvate 
carboxy kinase, that interconverts between phosphoenolpyruvate (glycolytic 
intermediate) and oxaloacetate (TCA cycle intermediate) or a serine-glycine pathway 
(phosphoglycerate dehydrogenase, phosphoserine transaminase, phosphoserine 
phosphatase, glycine hydroxymethyltransferase and glycine dehydrogenase 
(Figure 4-1). We hypothesise that a second metabolic or regulatory defect in glucose 
metabolism contributes to the M. bovis glucose phenotype, in addition to the inactive 
pyruvate kinase (80). The fact that in vitro complementation of M. bovis with pykA  (80) 
does not restore the ability to grow on glucose supports this hypothesis.
To further explore M. bovis glucose metabolism, M. bovis and M. tuberculosis were 
incubated with D-glucose for four hours. It was found that M. bovis  could uptake
a small amount of the labelled glucose but the rate was 16-fold less than 
M. tuberculosis, consistent with a defect in glucose uptake (Table 4-1). Interestingly, 
supplementation of the glucose media with Tween 80 significantly stimulated glucose 
uptake by M. bovis (2.5 times). However, the fate of this additional glucose was not 
oxidation to carbon dioxide as the amount of "^^0 -0 0 2  generated was unchanged by the 
Tween 80 supplementation.
Maximum growth rates and ODeoo achieved on these substrates also indicated 
synergistic interaction, as growth of M. bovis on Roisin’s media with glucose and 
Tween 80 exceeded that that achieved with either compound alone (Figure 4-2). 
Interestingly, M. bovis BCG which produces an active pykA  was also shown to exhibit 
the same growth phenotype as M. bovis (with inactive pykA) when grown under the 
same conditions (Figure 4-2).
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Figure 4-1; The in siiico prediction of flux from glucose to the TCA cycle intermediates when 
glucose is a sole carbon source for M. bovis.
Green: glycolytic reactions; Purple: phosphoenolpyruvate kinase; Red: flux through serine to the 
TCA cycle; Blue: TCA cycle and glyoxylate shunt.
Aeon: aconitase, C/Ï: citrate synthase, Eno: enolase, Fba: fructose-bisphosphate aldolase, Gck: 
glucokinase, Gdh: glycine dehydrogenase, GlcB: malate synthase, GlyA: glycine
hydromethytransferase, Gpm: phosphoglycerate mutase. Id: isocitrate lyase, Mdh: malate 
dehydrogenase, Pepck:, phosphoenolpyruvate carboxykinase, Pfk. 6-phosphofructokinase, Pgi: 
glucose-6-phosphate isomerise, SerA: phosphoglycerate dehydrogenase, SerB: phosphoserine 
phosphatise, SerC: phosphoserine transaminase, TpiA: triose-phosphate isomerase
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Table 4-1: Glucose uptake experiments in M. bovis and M. tuberculosis
Disintegrations per minute per mg dry weight Growth rates on non-radiolabelled substrates
M. tuberculosis M. bovis
Carbon substrates Assimilated Assimilated CO2 evolved Maximum growth rate
Maximum
OD
[6- '^^C] D-glucose 3396 +/- 190 208 +/- 53 63 +/- 9 - 0.015 +/- 0.004
Tween 80 N/A N/A N/A 0.007 +/- 0.001
0.545 +/- 
0.044
[O-^ '^ C] D-glucose 
and Tween 80 N/A 520 +/- 43 57 +/-19
0.013 +/- 
0.001
1.171 +/- 
0.066
Figure 4-2: Growth of M. bovis on glucose, glucose and Tween 80 and Tween 80 
■  M. bovis; #  M. bovis BCG
Green: glucose and Tween 80; Blue: Tween 80; Red: glucose
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4.3.2 Analysis of amino acid metabolism
Bioiog data and in siiico predictions were notably different for the utilisation of amino 
acids as sole carbon or nitrogen sources (Table 4-2) as the models predicted a greater 
metabolic potential than was actually demonstrated experimentally. Many of these 
discrepancies were resolved by the Roisin’s agar experiments, as more amino acids 
were shown to support growth in Roisin’s agar than were positive for respiration in 
Bioiog. Possible reasons for this include large differences in the incubation times for 
these experiments. In support of this theory, the amino acids that were found to be 
viable substrates for M. bovis  and M. bovis BCG in siiico and in Roisin’s agar, but not in 
the Bioiog experiments, predominantly produced dysgonic colonies with a lag time of 
around 6 -8  weeks on Roisin’s agar {M  bovis: arginine C, N; glutamine C; glutamate C; 
glycine C; isoleucine C, N; proline C; serine C, N; M. bovis BCG; arginine C, N; 
glutamine C, N; glycine C; isoleucine C; proline C; serine C). All amino acids that 
permitted growth of M. tuberculosis on Roisin’s agar displayed growth before 6 weeks.
Interestingly, the experimental data also showed that M. tubercuiosis was able to grow 
on a greater number of amino acids when they were supplied as nitrogen sources as 
compared to M. bovis to M. bovis BCG, with the number of viable substrates 
decreasing from M. tuberculosis to M. bovis to M. bovis  BCG. This was not however 
reflected by significant network differences.
4.3.2.1 Serine and glycine metabolism
The amino acid data regarding serine metabolism was of particular interest because 
the results differed between the three mycobacteria and appeared inconsistent with in 
siiico simulations, in siiico serine metabolism is relatively complex compared to other 
amino acids as multiple pathways converge around serine (Figure 4-3). However, in 
vitro only the interconversion of pyruvate and serine enables utilisation of serine as a 
sole nitrogen source, as some BCG strains, including M. bovis BCG Pasteur, are 
unable to utilise serine as a nitrogen source due to inadequate expression of sdaA 
(82). M. tuberculosis, which has been found to adequately express sdaA  can utilise 
L-serine (82) as can M. bovis strains (Table 4-2). in siiico, however, the GSMN-BCG 
inaccurately predicts that serine is a viable sole nitrogen source for M. bovis BCG with 
flux to glycine (serine hydromethyltransferase) enabling viability. The three 
mycobacteria used in this study have two serine hydromethyltransferases {giyA1 and
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glyA2), but enzyme activity has been demonstrated in M. tuberculosis only (187). The 
glyA1 of M. bovis and M. bovis BCG has an amino acid substitution as compared to 
M. tuberculosis but the effect on activity is not known. If the interconversion of serine 
and glycine is feasible in M. bovis BCG, this reaction doesn’t appear to take place 
when serine is supplied as sole nitrogen source (82). However, because serine was 
shown to be a viable sole carbon source for M. tuberculosis, M. bovis and 
M. bovis BCG, flux from serine must be able to enter the TCA cycle. The most probable 
route for this would be via glycine (Figure 4-3)
Table 4-2: The utilisation of amino acids as carbon and nitrogen sources by M. tuberculosis, 
M. bovis and M. bovis BCG.
0  utilised as a carbon source
N utilised as a nitrogen source
NT not tested
no respiration/growth
M. tuberculosis M. bovis M. bovis BCG
Biolog Roisin'sagar in silico Biolog
Roisin's
agar in silico Biolog
Roisin's
agar in silico
Number of 
viable amino 
acid
substrates
10 12 11 12 8 10 11 10 11
Alanine
Arginine
Asparagine
Aspartate
Cysteine NT NT NT
Glutamate
Glutamine
Glycine
Histidine
Isoleucine
Leucine
Lysine
Methionine
Phenylalanine
Proline_____
Serine______
Threonine
Tryptophan
Tyrosine
Valine
NT
NT
NT
NT
NT
NT
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Figure 4-3; Serine and glycine metabolism in mycobacteria
Blue: present in by M. tuberculosis H37Rv, M. bovis AF2122/97 and M. bovis BCG Pasteur (4- 
6), Red: present in M. tuberculosis H37Rv and M. bows AF2122/97 (5, 6, 82), Green: present in 
M. tuberculosis H37Rv and M. bovis BCG Pasteur (4-6), Purple: present in by
M. tuberculosis H37Rv (5, 83).
Aeon: aconitase, Cgl: cystathionine gamma-lyase Cit: citrate synthase, CysE, CysK1, CysK2: 
cysteine synthase, CysM: cystathionine beta-synthase, Eno: enolase, Gdh: glycine 
dehydrogenase, GlcB: malate synthase, GlyA: glycine hydromethytransferase, Gpm: 
phosphoglycerate mutase. Id: isocitrate lyase, Mdh: malate dehydrogenase, Pdh: pyruvate 
dehydrogenase, PykA: pyruvate kinase, Ppdk: pyruvate phosphate dikinase, SerA: 
phosphoglycerate dehydrogenase, SerB: phosphoserine phosphatise, SerC: phosphoserine 
transaminase, SdaA: serine deaminase
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4.S.2.2 Alanine metabolism
In M. tuberculosis aid catalyses the oxidative deamination of alanine or, in the reverse 
direction, the reductive amination of pyruvate to yield alanine, but this activity is lost (6, 
81-83) in M. bovis and M. bovis BCG due to a frameshift caused by single base pair 
deletion (6). Deletion of a/d from the bovine networks resulted in a non-feasible network 
(no growth) unless alanine was supplied as a substrate, since this is the only 
biosynthetic route leading to alanine in the network. Yet, in contrast to the predictions 
M. bovis and M. bovis BCG are not alanine auxotrophs, alanine dehydrogenase knock­
out mutants of M. tuberculosis are also not alanine autotrophs (81, 173, 174) and ^^ C 
labelling experiments detected identical alanine labelling pattems (164) for 
M. tuberculosis and M. bovis BCG; indicating that an alternative pathway for alanine 
synthesis must be active in all three strains. Therefore, the route of alanine synthesis in 
M. bovis and M. bovis BCG is currently unclear.
4.3.2.2.1 Analysis of potential alanine synthesising reactions
40 different reactions involving 35 enzymes are known to utilise alanine as substrate or 
product (143) (Table 4-3), the majority of which are aminotransferases. 
Aminotransferases are fundamentally reversible enzymes and were considered unlikely 
to synthesise alanine in M. bovis and M. bovis BCG, since these mycobacteria are 
unable to degrade alanine (81, 82) (indicating the likely irreversible nature of their 
alanine synthesising enzyme).
Analysis of the non-aminotransferase enzymes identified aspartate-|3-decarboxylase, 
which acts on the (3-carboxyl group of aspartate to yield alanine and CO2 (188, 189) as 
a potential enzyme for the synthesis of alanine in M. bovis and M. bovis BCG. 
Aspartate-P-decarboxylase was considered a suitable enzyme because the amount of 
aspartate in the mycobacterial cell is likely to be much greater than other potential 
alanine producing substrates e.g. alanopine, L-kynurenine and 2,2-dialkylglycine. 
Therefore the availability of aspartate is less likely to be rate-limiting.
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Table 4-3: Reactions known to involve alanine
E.G. Number Enzyme Reaction
1.14.13.41 Tyrosine N-monooxygenase L-Amino acid + Oxygen + NADPH <=> N-Hydroxy-amino acid + NADP+ + H20
1.4.1.1 Alanine dehydrogenase L-Aianine + NAD+ + H20 <=> Pyruvate + NH3 + NADH + H+
1.5.1.17 Alanopine dehydrogenase Alanopine + NAD+ + H20 <=> L-Alanine + Pyruvate + NADH + H+
2.3.1.47 8-amino-7-oxononanoate synthase 6-Carboxyhexanoyl-CoA + L-Aianine <=> 8-Amino-7-oxononanoate + CoA + C02
2.6.1.- Putrescine:pyruvateaminotransferase Putrescine + Pyruvate <=> 4-Aminobutyraldehyde + L-Alanine
2.6.1.12 L-aianine:oxaioacetateaminotransferase
L-Alanine + Oxaloacetate <=> Pyruvate + L-Aspartate
L-Alanine + 2-Oxo acid <=> Pyruvate + L-Amino acid
2.6.1.15 Giutamine-pyruvate transaminase L-Glutamine + Pyruvate <=> 2-Oxogiutaramate + L-Alanine
2.6.1.18 Beta-alanine-pyruvate transaminase
L-Alanine + 3-Oxopropanoate <=> Pyruvate + beta-Alanine
L-Alanine + (S)-Methyimalonate semiaidehyde <=> Pyruvate + L-3-Amino- 
isobutanoate
2.6.1.2 L-Alanine;2-oxogiutarateaminotransferase L-Alanine + 2-Oxoglutarate <=> Pyruvate + L-Glutamate
2.6.1.30 Pyridoxamine-pyruvatetransaminase Pyridoxamine + Pyruvate <=> Pyridoxal + L-Alanine
2.6.1.37 2-am inoethyl phosphonate-pyru vate transaminase 2-Aminoethylphosphonate + Pyruvate <=> Phosphonoacetaldehyde + L-Alanine
2.6.1.40 (R)-3-amino-2-methylpropionate- pyruvate transaminase
(R)-3-Amino-2-methylpropanoate + Pyruvate <=> 2-Methyl-3-oxopropanoate + L- 
Alanine
2.6.1.41 D-methionine-pyruvate transaminase D-Methionine + Pyruvate <=> 4-Methylthio-2-oxobutanoic acid + L-Alanine
2.6.1.43 Aminolevulinate transaminase 5-Aminolevulinate + Pyruvate <=> 4,5-Dioxopentanoate + L-Alanine
2.6.1.44 L-Alanine:glyoxylateaminotransferase L-Aianine + Glyoxylate => Pyruvate + Glycine
2.6.1.46 Diaminobutyrate-pyruvatetransaminase L-2,4-Diaminobutanoate + Pyruvate <=> L-Aspartate 4-semialdehyde + L-Alanine
2.6.1.47 Alanine-oxomalonate transaminase Pyruvate + Aminomalonate <=> L-Alanine + Oxomalonate
2.6.1.51 Serine-pyruvate transaminase L-Serine + Pyruvate <=> Hydroxypyruvate + L-Alanine
2.6.1.56 Guanidinoaminodideoxy-scylio- inositol-pyruvate aminotransferase
1D-1-Guanidino-3-amino-1,3-dideoxy-scyilo-inositol + Pyruvate <=> 1D-1- 
Guanidino-1-deoxy-3-dehydro-scyilo-inositol + L-Alanine
2.6.1.58 Phenylalanine (histidine) transaminase L-Phenylaianine + Pyruvate <=> Phenyipyruvate + L-Alanine
2.6.1.66 Valine-pyruvate transaminase L-Valine + Pyruvate <=> 3-Methyi-2-oxobutanoic acid + L-Alanine
2.6.1.71 Lysine-pyruvate 6-transaminase L-Lysine + Pyruvate <=> L-2-Aminoadipate 6-semialdehyde + L-Alanine
2.6.1.77 Taurine-pyruvate aminotransferase Taurine + Pyruvate <=> Sulfoacetaldehyde + L-Alanine
2.6.1.84 Arginine-pyruvate transaminase L-arginine + pyruvate = 5-guanidino-2-oxopentanoate + L-alanine
2.8.1.7 Cysteine desulfurase [Enzyme]-cysteine + L-Cysteine <=> [Enzyme]-S-sulfanylcysteine + L-Alanine
3.5.1.28 N-acetyimuramoyl-L-alanineamidase N-Acetylmuramoyl-Ala + H20 <=> N-Acetylmuramate + L-Aianine
3.5.5.1 Nitrilase aipha-Aminopropiononitrile + 2 H20 <=> Alanine + NH3
3.7.1.3 Kynureninase
L-kynurenine + H20 <=> anthranilate + L-alanine
3-Hydroxy-L-kynurenine + H20 <=> 3-Hydroxyanthraniiate + L-Aianine
L-Formyikynurenine + H20 <=> Formylanthraniiate + L-Alanine
4.1.1.12 L-aspartate 4-carboxylyase or aspartate 4-decarboxyiase
L-Aspartate <=> L-Aianine + C02
3-Sulfino-L-alanine <=> L-Aianine + Sulfur dioxide
4.1.1.64 2,2-dialkyiglycine decarboxylase 2,2-Dialkylglycine + Pyruvate <=> Dialkyl ketone + C02 + L-Alanine
4.4.1.16 Selenocysteine lyase L-Selenocysteine + Reduced acceptor <=> Selenide + L-Alanine + Acceptor
5.1.1.1 Alanine racemase L-Alanine <=> D-Alanine
6.1.1.7 Alanine-trna iigase ATP + L-Alanine + tRNA (Ala) <=> AMP + Diphosphate + L-Alanyl-tRNA
6.3.28 UDP-N-acetylmuramate-L-alanineIigase
ATP + UDP-N-acetylmuramate + L-Alanine <=> ADP + Orthophosphate + UDP- 
N-acetyimuramoyl-L-alanine
N-acetyldemethylphosphinothricin:L- 
alanine:L-alanine Iigase (AMP- 
forming)
N-Acetyidemethylphosphinothricin + 2 L-Alanine + 3 ATP + H20 <=> N- 
Acetyidemethyiphosphinothricin tripeptide + 3 AMP + 3 Diphosphate
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4.S.2.2.2 LC-MS analysis of alanine synthesis
Paul Wheeler (AHVLA) designed the sample preparation method and grew the cells. 
Lysate preparation, lysate incubation, PTC derivatisation and HPLC preparation was 
carried out jointly with equal participation.
Janine Gielbert (AHVLA) and Paul Wheeler designed the LC-MS method.
LC-MS sample analysis was carried out jointly with Janine Gielbert
LC-MS (183) analysis was used to try to detect aspartate-P-decarboxylase activity and 
the synthesis of alanine from aspartate. Cell lysates were incubated with aspartate or 
aspartate and either pyruvate or a-ketoglutarate (stimulants of 
aspartate-p-decarboxylase activity (189)). Negative controls containing ammonia and 
pyruvate (catalysed to alanine by aid) were also tested (6). LC-MS analysis revealed 
that addition of aspartate to lysates of M. tuberculosis, M. bovis and M bovis BCG 
resulted in synthesis of alanine, and the addition of aspartate-P-decarboxylase inducers 
(pyruvate and a-ketoglutarate) resulted in higher levels of alanine produced 
(Table 4-4). Low levels of alanine were also detected when ammonia and pyruvate 
were added to M. bovis and M. bovis BCG lysates. The presence of alanine in these 
samples was indicative of high background levels of alanine detected in the cell 
lysates. The initial experiments also showed that the increase in alanine concentration 
over time was not linear.
In order to rectify the problems of high background levels of alanine and the non-linear 
increase in alanine synthesis over time, alterations were made to the sample 
procedure. Samples contained 5 pi or 2 pi of cell lysate rather than the initial amount of 
50 pi to reduce background levels of alanine, duplicate samples using 5 pi of cell lysate 
were inactivated using methanesulphonic acid and ethanol heated to 80“C to 
definitively inactivate cell lysates, and samples were also taken after 1 and 2 min in 
order to generate a more accurate time course. However, these changes failed to 
resolve the experimental issues and in fact these alterations generated much less 
satisfactory data (data not shown) than the initial experiment. Therefore, our 
experiments demonstrated that LC-MS is an unsuitable method for the detection of 
alanine production in mycobacteria.
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4.3.2.2.S Colorimetric assays for the detection of alanine synthesis
Due to the unreliability of LC-MS for the analysis of alanine synthesis, continuous 
colorimetric assays were trialled to detect alanine production in cell lysates. Initial 
experiments focused on identifying aspartate-p-decarboxylase activity using either an 
L-amino acid oxidase assay (185) or a coupled alanine dehydrogenase assay, but due 
to high background readings and/or lack of enzyme activity (data not shown) activity 
was not detected.
Another potential enzyme for alanine synthesis is alanine transaminase. Alanine 
transaminase (alanine + a-ketoglutarate = pyruvate + glutamate) was investigated due 
to the indication that alanine is produced from a glycolytic substrate (164). However, 
colourmetric assays (186) failed to detect alanine transaminase activity (data not 
shown). Despite our best efforts the reactions involved in alanine synthesis remain to 
be elucidated.
Table 4-4: Alanine detected in cell lysates incubated with aspartate 
mean ± standard error for duplicate experiments
Alanine concentrations (nmols/mg protein)
Time
(min) M. tuberculosis M. bovis M. bovis BCG
25mM aspartate
0 703 +/-163 918+7-557 523 +7- 740
5 669 +/-218 1131 +/-240 365 +7-516
50 887 +/- 78 1469 +/-206 1320 +7-28
25mM aspartate, 1 mM 
a-ketoglutarate
0 1125 3137 0
5 1149 4443 7
50 1947 4125 308
25mM aspartate, 1 mM 
pyruvate
0 8646 15877 697
5 7407 17961 964
50 5454 17629 1574
1 mM aspartate
0 293 +/- 22 583 +/- 331 0+7-0
5 167 +/- 64 719+7-90 0+7-0
50 328 +/- 21 794 +7- 201 293 +7- 11
1 mM aspartate, 1 mM 
a-ketoglutarate
5 347 684 0
50 149 506 216
ImM aspartate, ImM 
pyruvate
5 0 4130 206
50 0 4738 651
25mM ammonia, ImM 
pyruvate
5 0 +/- 0 136 +7-84 132 +7-186
50 0+/-0 405 +7-1 74 +7-105
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4.4 Discussion
Genome scale modelling drives metabolic discovery, thus making our knowledge of 
metabolism more complete. Therefore, in addition to validating the networks we have 
used in silico and in vitro comparisons to generate experimentally testable hypotheses 
and further metabolic knowledge. For instance, the model predicted growth of M. bovis 
on glucose. This is contrary to expectations as this inability is a distinguishing feature of 
M. bovis strain of the tubercle bacillus. Presumably, the pathways utilised in silico to 
connect between glycolysis and the TCA cycle are not able to support growth in vitro 
(80) and additional defects, such as the identified glucose transport deficit are also 
contributing to this phenotype.
Our studies show that despite being unable to utilise glucose as sole carbon source, 
the sugar can be assimilated by M. bovis. Indeed, glucose assimilation was stimulated 
by addition of Tween 80 to the glucose media. Tween 80 is hydrolysed by 
mycobacteria to release fatty acids, such as oleic acid, that may be oxidised to acetate 
and thereby enter the TCA cycle to support the synthesis of essential metabolic 
precursors, such as oxaloacetate and a-ketoglutarate, as well as providing substrates 
for energy generation. The result suggests that M. bovis is capable of assimilating 
carbohydrates such as glucose, but not delivering carbon from those substrates to the 
TCA cycle; as the additional glucose was not oxidised to CO2 and was presumably 
incorporated directly into cell biomass. It is interesting that this disconnect is 
unidirectional: M. bovis can utilise acetate as a sole carbon source so must be able to 
drive flux from acetate to glucose via gluconeogenic pathways. The result is consistent 
with a previous study that demonstrated compartmentalisation during co-utilisation of 
different substrates in M. tuberculosis (71). When supplied with both carbohydrate 
(such as glucose) and fatty acid (acetate), the carbohydrate was assimilated via 
glycolysis and the pentose phosphate cycle and mostly incorporated into biomass; 
whereas acetate was mainly used for energy generation via the TCA cycle (71).
Another key discrepancy between the networks and in vitro observations was that the 
in silico models predicted greater metabolic potential than demonstrated in vitro. The 
reduction in in vitro substrate utilisation capability was particularly evident for bovine 
tuberculosis strains, as substrate utilisation capability decreased from 
M. tuberculosis > M. bovis > M. bovis BCG. It seems that during their evolutionary 
passage from their common ancestor (that is presumed to be close to M. tuberculosis 
(16)), M. bovis and M. bovis BCG have lost some of their capability to metabolise
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compounds. This observation was clearly demonstrated by the comprehensive testing 
of amino acid utilisation as sole nitrogen sources.
The basis of the observed loss in metabolic versatility is mostly unknown, as the 
majority of discrepancies are not reflected by current genetic or enzymatic knowledge. 
A potential reason for this reduction in metabolic capacity is a deficiency in substrate 
transport. It has been shown here (M. bovis, glucose metabolism) and previously 
{M. tuberculosis, lysine metabolism (190)) that a reduction in transport efficiency can 
contribute to the inability or reduced ability to metabolise substrates on defined media. 
Few transporters have been identified in M. tuberculosis, M. bovis and M  bovis BCG, 
but of the 12 predicted amino acid transporters"^ '®'^ ®^ '^ ®^  Rv1979c is missing in 
M. bovis BCG due to the RD2 (4, 62, 191) deletion. Other possible explanations for the 
observed loss in substrate catabolism include unidentified mutations within enzyme 
sequences or differences in gene regulation.
Our studies also identified that some amino acids, such as serine, could act as carbon 
but not nitrogen sources, indicating that the pathways responsible for amino acid 
degradation differ for carbon and nitrogen assimilation. M. tuberculosis, M. bovis and 
M.bovisBCG were able to assimilate nitrogen from 12, 8 and 6 amino acids 
respectively, despite almost identical in silico predictions, but could utilise similar 
numbers of amino acids as carbon sources. These experiments highlight a limitation of 
FBA predictions, in which any route for flux from substrates to products may be utilised 
by the solution. The only difference In silico is the ability of M tuberculosis to utilise 
alanine as a nitrogen and carbon source in contrast to M. bovis and M. bovis BCG. This 
difference corresponds to the previously mentioned mutation in the aid gene in M. bovis 
and M. bovis BCG, indicating that, in accordance with previous studies (81, 82) this 
gene is required for alanine assimilation.
Aid has previously been hypothesised as an important enzyme as it is one of the 
predominant secretory antigens in culture filtrate (192), and is overproduced during 
hypoxic (193) and nutrient starved conditions (86). However, aid is not associated with 
the attenuated phenotype of M. bovis BCG and does not influence the protective 
efficacy of the vaccine against M. tuberculosis (194). Removal of aid from the bovine 
networks created a pathway hole resulting in predicted alanine auxotrophy, since this is 
the only biosynthetic route leading to alanine in the network. This prediction is in 
contrast to in vitro observations and indicates the presence of a yet to be discovered
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alanine synthesising reaction in M. bovis and M. bovis BCG strains. The inability of 
M. bovis, M. bovis BCG and M. tuberculosis Aald to assimilate alanine from growth 
media (81-83) indicates the alanine synthesising reaction is irreversible and no other 
reaction able to degrade alanine exists in these mycobacteria. The unidentified reaction 
is also likely to act as the predominant alanine synthesising reaction in M. tuberculosis, 
as identical alanine labelling patterns in M. tuberculosis and M.bovisBCG (164) 
indicate that the carbon backbone is generated from the same precursors. 
Consequently, we hypothesise that aid is primarily used for catabolic purposes in 
M. tuberculosis {^64).
Metabolic networks essentially collate existing hypotheses which when combined 
enable the identification and investigation of new hypotheses. Novel findings are fed 
back into the network development process with this iterative cycle of traditional and 
computational approaches enabling the advancement of metabolic knowledge. 
Through the investigation of discrepancies between in silico and in vitro data we have 
shown that these metabolic models have the potential to contribute to our 
understanding of the metabolism of the bovine forms of tuberculosis. Continual 
investigation into areas of metabolism which differ between the three networks and in 
vitro observations may help to stimulate new understanding of metabolism on a global 
scale and aid in our understanding of pathogenic differences.
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The Unified-TB network visualised using Cytoscape (127)
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5.1 Introduction
The construction of genome scale reaction networks involves an iterative sequence of 
network curation, so as to generate a model which is both biochemically correct and 
reproduces in vitro data accurately. Iterative development is when a series of 
processes is executed multiple times with each cycle called an iteration. In the 
construction of metabolic networks the initial step creates and analyses the first version 
of the network, whilst further cycles of development aim to generate an improved 
network. Each cycle incorporates novel data, including information learned during the 
curation and analysis of previous versions of the network, or from hypothesis driven 
investigations conceived from the analysis of in silico predictions. Recently, the iterative 
development process has also began to integrate concurrent reaction networks 
generated for the same microorganism (114), as only 39 of the 59 reconstructions 
available represent a unique species (114).
Currently there are three main versions of genome scale metabolic networks that 
represent the cellular metabolism of M. tuberculosis fGSMN-TB, iNJ661 and 
Metamerge). The first reaction networks, GSMN-TB (115) and iNJ661 (116), were 
published in 2007, with updates to GSMN-TB leading to GSMN-TB 1.1 (Appendix 1) 
and iNJ661 undergoing corrections (iNJ661m (126)) and adaptation using in vivo data 
(iNJ661v (126)). The availability of different genome scale metabolic networks lead to 
the creation of an algorithm (Metamerge) (114) for semi-automatically combining two 
existing models into a single metabolic network. Metamerge was used to integrate 
GSMN-TB and iNJ661 into a combined model (114).
The amalgamation of coexisting reaction networks has been a significant progression in 
network development, as due to the large number of literature sources available, 
individual curation preferences (metabolites and reactions may be sub-classified and 
many genes are only tentatively annotated) and the lack of a universal naming 
convention, the comparison of reaction networks representing the same species is 
difficult. Whilst the creation of the Meta merge network is an important development, the 
combined network did not implement updates to network pathways nor reconfirm the 
validity of model entities during the construction process. Additionally, the network is 
validated against TraSH (174) gene essentiality data, but not results generated by deep 
sequencing (173), and doesn’t include comparisons of substrate utilisation or growth 
rates. Therefore, there is the need for a combined network that has undergone manual
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confirmation of network entities, as metabolic theories are constantly revised, and a 
greater range of metabolic comparison against laboratory generated results.
5.1.1 Aims
Metabolic reaction networks require iterative development in order to accurately 
represent the system it intends to characterise. Therefore, the aim of this study was to 
update the GSMN (115) reaction networks by integrating data from iNJ661 (116), 
incorporate recently published findings and to utilise datasets previously used to 
ascertain predictive accuracies in the refinement process.
5.2 Methods
5.2.1 Construction of the Unified reaction networks
Kieran Smallbone (University of Manchester) annotated the model using Miriam (195)
standards, carried out the work using the SuBliMinaL toolbox (196) (assigned
metabolites a ChEBI identifier (197), verified E.G. numbers, mapped genes to 
TubercuList (198), predicted charge state for each molecule at neutral pH, ensured that 
reactions were stoichiometrically balanced and carried out automatic reaction 
matching).
Ahmed Mannan (University of Surrey) jointly constructed the Biomass formulation. 
Huihai Wu (University of Surrey) generated a script for the conversion of GSMN 
metabolite nomenclature into iNJ661 nomenclature.
GSMN-TB 1.1 (Appendix 1) and iNJ661 (116) (Appendix 27) were annotated using
‘Minimum Information Required In The Annotation of Models' (MIRIAM) (195)
standards for unambiguous identification. This allowed merging with the SuBliMinaL 
toolbox (196). The SuBliMinaL toolbox (196) assigned metabolites a ChEBI identifier 
(197) (e.g. http://identifiers.Org/obo.chebi/CHEBI:456216), reactions an E.C. number 
(e.g. http://identifiers.Org/ec-code/2.7.1.30) and mapped genes to TubercuList (198) 
(e.g. http://identifiers.org/myco.tuber/Rv3696c). The protonate module was used to 
predict charge state for each molecule at neutral pH and the balance module ensured 
that reactions were stoichiometrically balanced. 297 reactions were then found in 
common between both networks using the merge module. Manual reaction matching 
identified a further 195 reactions that, whilst not stoichiometrically identical, were meant
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to represent the same reaction in each network. For these reactions, and metabolic 
pathways with differing metabolite production in GSMN-TB 1.1 and iNJ661 (116), the 
TB database (144, 145) and KEGG (143) were used to identify which reactions to 
include. The TB database (144, 145) and published literature were then used to 
implement updates to reaction pathways and check gene annotations. Metabolite 
nomenclature was based on the Palsson convention system with GSMN metabolites 
without a standard identifier named either by following the implemented naming pattern 
or by their KEGG identifier. The biomass objective function was based on the iAF1260 
model of E. coli K12 (108) and modified to reflect the mycobacterial cell composition 
(115, 176). The workflow described above using the SuBliMinaL toolbox (196) (minus 
the merge module) was then reapplied to the final network.
The updated M. tuberculosis model is made available in the appendices (Appendices 
28 - 29) and M. bovis and M. bovis BCG versions of the updated network are also 
available (Appendices 30 - 33). These networks were generated by the removal of 
components from the M. tuberculosis network as defined in Table 2-2, as well as other 
alterations identified since the curation of the bovine GSMN networks (199-201).
5.2.2 Biolog phenotype experiments
Refer to 3.2.2: Biolog phenotype experiments
5.2.3 Roisin’s media phenotype experiments
Refer to 3.2.1: Bacterial strains and growth conditions
5.2.4 Modeliing of phenotype experiments
Huihai Wu (University of Surrey) generated a script to carry out In slllco phenotype 
experiments
A python script was written in order to perform the modelling of phenotype experiments 
in batch. The script used three parameters: SurreyFBA command line, problem file and 
output file. Nutrient uptake rates for fixed substrates were defined with the comment 
‘#fix’ and remaining transporters were automatically tested for the ability of the
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exchange metabolite to enable growth. Refer to ‘3.2.3: Modelling of phenotype 
experiments’ for nutrient uptake conditions.
5.2.5 Modelling of growth rate experiments
Refer to 3.2.4: Modelling of growth rate experiments
5.2.6 Gene essentiality prediction and comparison with TraSH and 
deep sequencing data
Gene essentiality predictions were generated as for ‘3.2.5: Gene essentiality 
predictions and comparison with TraSH and deep sequencing data’, except that biotin 
was not available to INJ661 (116) and iNJ661m (126) networks due to the lack of 
exchange flux.
5.3 Results
5.3.1 Reconstruction of the M. tuberculosis reaction network
Kieran Smallbone (University of Manchester) annotated the model using Miriam (195) 
standards, carried out the work using the SuBliMinaL toolbox (196) (assigned 
metabolites a ChEBI identifier (197), verified E.C. numbers, mapped genes to 
TubercuList (198), predicted charge state for each molecule at neutral pH, ensured that 
reactions were stoichiometrically balanced and carried out automatic reaction 
matching)
The Biomass formulation was constructed jointly with Ahmed Mannan (University of 
Surrey).
Huihai Wu (University of Surrey) generated a script for the conversion of GSMN 
metabolite nomenclature into iNJ661 nomenclature.
The iterative model development process primarily involved the merging of two 
genome scale metabolic networks of M. tuberculosis, GSMN-TB 1.1 (Appendix 1) and 
iNJ661 (116), augmented with the inclusion of novel data. Both automated and manual 
procedures were included to ensure the completed network functioned as a unique 
model and reactions or pathways were not duplicated due to differences in reaction
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curation between the two networks. The SuBliMinaL toolbox (196) was used to match 
metabolites, reactions and genes to their corresponding entry in the ChEBI and 
TubercuList databases (197, 198), predict charge state at neutral pH, stoichiometrically 
balance the reaction formulae and identify identical reactions in both networks. Manual 
curation recognised further reactions meant to represent the same process whilst not 
being stoichiometrically identical. A range of published literature was then used to 
reconstruct the network from the data provided by both networks. Our aim was to have 
standardised identifiers as metabolites are annotated differently between the existing 
networks. Therefore, metabolite nomenclature was based on the widely-used Palsson 
convention system with GSMN metabolites without a standard identifier named either 
by following the implemented naming pattern or by their KEGG identifier (143). The 
biomass objective function was constructed via adaptation of the formula from the 
iAF1260 model of E. coli K12 (108) using data compiled on the mycobacterial cell 
composition (115,176).
This initial model was expanded in size by the incorporation of novel reactions, genes 
and metabolites, based on published literature and high-throughput Biolog phenotyping 
data (83, 144, 145, 173, 199-211). For instance, our understanding of cholesterol 
degradation has advanced since the original networks were constructed (144, 145, 
173, 202-209) and the expansion of this reaction pathway accounted for the majority of 
additional reactions.
The Unified-TB network is provided in both SBML (212) (Appendix 28) and as an excel 
spreadsheet which includes all accompanying data (Appendix 29).
5.3.1.1 Construction of M. bovis and M. bovis BCG reaction 
networks
Adaptation of Unified-TB to reflect M. bovis and M. bovis BCG metabolism followed the 
alterations set out in Table 2-2 with an additional modification: the M. bovis BCG 
network was not annotated with a gene equivalent to the arginine transport protein 
Rv1970 (199-201). Unified-MB and BCG are available as both SBML files and excel 
spreadsheets (Appendices 30 - 33).
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5.3.2 M. tuberculosis reaction network statistics
The characteristics of Unified-TB are detailed in Table 5-1. Generally, the network has 
a broader scope than the two original reaction networks (115, 116) (Table 5-1) and a 
modified version of iNJ661, iNJ661m (126); containing more reactions, genes and 
metabolites. The completed reconstruction contains: 1006 reactions (492 from both 
models; 369 from GSMN-TB 1.1 only; 102 from INJ661 only; 43 new reactions), 806 
genes (483 from both models; 250 from GSMN-TB 1.1 only; 54 from INJ661 only; 19 
new genes) and 901 metabolites (503 from both models; 252 from GSMN-TB 1.1 only; 
111 from iNJ661 only; and 35 new metabolites). As compared to the Metamerge 
combined M. tuberculosis network (114), Unified-TB contains fewer reactions, genes 
and metabolites (Table 5-1). These differences are due to the different methods 
applied during network curation and the employment of criteria cut-offs before the 
inclusion of data. For instance, during curation of the Metamerge network reactions 
were only considered identical if their stoichiometry was identical and the number of 
reactions included was a method of network assessment (114). However, for Unified- 
TB, reactions were considered to be from both networks if the process represented 
was the same, even if their reaction stoichiometry differed. In these cases published 
literature was used to determine which reaction was correct. Also, GSMN-TB 1.1 and 
iNJ661 (116) entities were only included after analysis of reaction databases (143-145), 
published literature and the confidence level system implemented in iNJ661 (116).
Table 5-1: Network statistics of in vitro M. tuberculosis reaction networks
Reaction network
Reaction Class Unified-TB GSMN-TB 1.1 iNJ661 iNJ661m Metamerge
Total number of 
reactions 1006 876 1027 1049 1400
Cytosolic
reactions 816 745 939 953 1207
Transport
reactions 190 131 88 96 193
Genes 806 759 661 663 917
Total number of 
metabolites 901 766 828 838 1017
Internal
metabolites 753 667 740 742 880
External
metabolites 151 97 88 96 137
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5.3.2.1 M. bovis and M. bovis BCG reaction network statistics
The updated reaction networks representing the metabolism of M. bovis and 
M. bovis BCG have a broader scope than their equivalent GSMN network. Unified-MB 
and BCG contain 992/990 reactions, 765/766 genes and 894/891 metabolites 
respectively, as compared to the GSMN networks with 863/861 reactions, 718/720 
genes and 757/754 metabolites. Due to the similarities in constructing the bovine 
GSMN and Unified networks both versions include fewer reactions, genes and 
metabolites than their corresponding M. tuberculosis network. This is consistent with 
their hypothesised history of reductive evolution (16).
5.3.3 Analysis of reaction pathway coverage
The metabolic pathways that are included in the Unified reaction networks are the 
same as those within their corresponding GSMN network. During the integration of 
GSMN-TB 1.1 (Appendix 1) and iNJ661 (116) each pathway category has undergone 
alteration and expansion, but the overall network coverage of reaction subsets has 
remained comparable (Figure 5-1; Figure 2-1). All three mycobacterial networks have a 
similar percentage of the network covered by each pathway classification due to their 
genetic and metabolic similarity, with a large number of reactions dedicated to 
substrate uptake and lipid and amino acid metabolism.
Figure 5-1; Network coverage of each reaction pathway in Unified-TB
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5.3.4 Validation of the Unified networks
5.3.4.1 Accuracy of the Unified networks at predicting phenotype
data
Huihai Wu (University of Surrey) generated a script to carry out in silico phenotype 
experiments
Unified-TB, MB and BCG simulated both Biolog and combined phenotype data (Biolog 
and Roisin’s agar sole carbon and nitrogen sources) with slightly greater accuracy than 
the original GSMN reaction networks (Table 5-2; Appendices 34 - 39). The observed 
improvement predominantly relates to the network expansion undertaken after 
comparison between GSMN networks and substrate utilisation experiments (3.3.1; 
Validation of the GSMN reaction networks by comparison with phenotype data). Unlike 
previously published M. tuberculosis networks Unified-TB incorporates exchange and 
hypothetical degradation reactions for butanoic acid, oxalomalic acid, mono methyl 
succinate and methyl pyruvate; as all four substrates were utilised by M. tuberculosis, 
M. bovis and M. bovis BCG in vitro (177) (Table 3-1). Candidate reactions that could 
enable substrate degradation were incorporated after analysing metabolic pathways in 
KEGG (143), the substrates already incorporated into Unified networks, and using the 
SuBliMinaL toolbox (196). It is of note that although these degradation reactions are 
required for the observed catabolism, they are currently hypothetical with no 
corresponding genetic or biochemical evidence of their existence.
Using our simulation method iNJ661 (116) and iNJ661m (126) could not generate 
Biomass when testing viable sole carbon and nitrogen sources. This finding indicates a 
requirement for additional substrates to be available to the networks, such as the 
reported need for glycerol supplementation (116). The combined Metamerge (114) 
network was also unable to produce Biomass when simulated under our nitrogen 
source experiment, however, it reproduced our sole carbon source Biolog and 
combined phenotype data with an accuracy of 77% and 83% respectively (Appendix 
40)
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Table 5-2: Percentage accuracy of GSMN and Unified networks at predicting sole carbon and 
nitrogen source phenotype data
GSMN-TB 1.1 Unified-TB GSMN-MB Unified-MB GSMN-BCG Unified-BCG
Biolog Carbon 85 87 82 83 84 85
Nitrogen 82 83 81 82 84 84
Overall
accuracy 84 85 81 83 84 85
Combined Carbon 90 92 87 88 90 91
phenotype Nitrogen 92 93 86 88 87 88
Overall
accuracy 91 92 87 88 88 90
S.3.4.2 Accuracy of the Unified networks at representing growth 
rates
The Unified-TB and BCG reaction networks were used to simulate published 
experimental data (164) on substrate uptake rates and corresponding growth rates, 
with both networks computing slightly higher growth rates than observed with in vitro 
grown M. bovis BCG (164) (Table 5-3). These in silico predictions are also higher than 
those generated by the GSMN reaction networks (Table 5-3).
We could not compute growth rates via this method for iNJ661 (116), iNJ661m (126) 
nor the Metamerge (114) network.
Table 5-3: Comparison of in silico and in vitro growth rates on Roisin’s minimal media using 
calculated substrate uptake rates.
Specific
consumption rate 
(mmol g 
biomass h'^ )
M. bovis BCG GSMN-TB 1.1 Unified-TB GSMN-BCG Unified-BCG
in vitro 
growth rate 
(h-')
in silico 
growth rate 
(h-')
in silico 
growth rate 
(h-')
in silico 
growth rate 
(h-')
in silico 
growth rate 
(h-')
Glycerol 0.390 0.010 0.010 0.017 0.009 0.015
Tween 80 0.002
Glycerol 0.740
0.030 0.030 0.048 0.030 0.044
Tween 80 0.090
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5.3.5 Validation of the models by comparison with global
mutagenesis data
The impact of single gene deletions on the ability to produce Biomass was analysed for 
Unified-TB, MB and BCG, along with iNJ661 (116), iNJ661m (126) and the Metamerge 
(114) network (Appendices 41 -46). in silico predictions for all networks were carried 
out using the method outlined in ‘3.2.5: Gene essentiality predictions and comparison 
with TraSH and deep sequencing data’ in order to eliminate any variables between our 
methods and the simulations previously undertaken (114, 116, 126). However, INJ661 
(116) and INJ661m (126) do not have biotin exchange fluxes so biotin was not 
available to these networks.
5.3.5.1 Gene essentiality predictions
Overall, the percentage of essential genes within the Unified-TB network (27%) 
(Appendix 41) is in-between the values calculated for GSMN-TB 1.1 (29%) 
(Appendix 16) and iNJ661 (116) (18%) (Appendix 44). This value is similar to the 
number of genes determined to be essential within the iNJ661m network (126) (24%) 
(Appendix 45) and higher than that calculated for the Metamerge (114) network (13%) 
(Appendix 46). The reduction in essential genes observed between GSMN-TB 1.1 and 
Unified-TB is also reflected by the corresponding M. bovis and M. bovis BCG reaction 
networks (31% > 30% and 30% > 29% respectively) (Appendices 42 - 43).
For all three Unified networks the percentage of essential genes calculated in silico is 
lower than predicted value of 35% essential genes in the entire M. tuberculosis 
genome (181), and either just inside (Unified-MB and BCG) or outside (Unified-TB) the 
95% confidence interval, (28-41%). The result generated by iNJ661m (126) is also 
just outside these confidence intervals. However, INJ661 (116) and the Metamerge 
(114) network predict a lower number of essential genes than indicated from this 
genome analysis (181).
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S.3.5.2 Accuracy of the reaction networks at predicting global
mutagenesis data
Huihai Wu (University of Surrey) calculated p-values
In silico gene essentiality predictions for Unified-TB, MB and BCG were compared with 
in vitro gene essentiality data as determined by TraSH (174) and deep-sequencing 
(173) (Appendices 41 -43). Comparison with both datasets showed that the updated 
reaction networks reproduced in vitro gene essentiality data slightly more efficiently 
than the original GSMN reaction networks, with Unified-MB demonstrating the greatest 
increase in accuracy (Table 5-4; Table 5-5). The Unified-TB network also predicts gene 
essentiality with greater predictive accuracy that the alternative M. tuberculosis reaction 
networks. These networks generate percentage accuracies of: iNJ661 (116), 58% deep 
sequencing, 59% TraSH; iNJ661m (126), 66% deep sequencing, 64% TraSH;
Metamerge network (114), 67% deep sequencing, 65% TraSH. Using our simulation
method iNJ661 and iNJ661m predict TraSH data more accurately than originally 
reported (116, 126), whilst the Metamerge network had a lower predictive accuracy 
(114). For each network investigated ~81 -2% of genes had corresponding in vitro 
results available within the TraSH dataset (174) and all genes were able to be 
compared against equivalent data generated by deep sequencing analysis (173).
Table 5-4: Analysis of gene essentiality predictions by Unified-TB, MB and BCG reaction 
networks as compared to TraSH analysis (174)
Percentage of in silico gene essentiality predictions categorised as:
True-positive (essential both in the model and experiment)
False-positive (essential in the model, nonessential in experiment)
True-negative (nonessential in the model and experiment).
False-negative (nonessential in the model, essential in experiment).
GSMN-TB 1.1 Unified-TB GSMN-MB Unified-MB GSMN-BCG Unified-BCG
True positive 23% 22% 24% 24% 24% 23%
False positive 8% 8% 8% 8% 8% 8%
False negative 16% 15% 16% 14% 16% 15%
True negative 53% 56% 51% 54% 51% 54%
Correct
predictions 77% 77% 76% 78% 76% 77%
p value 0.005 0.004 0.011 0.028 0.008 0.006
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Table 5-5: Analysis of gene essentiality predictions by Unified-TB, MB and BCG reaction 
networks as compared to deep sequencing analysis (173)
Percentage of in silico gene essentiality predictions categorised as: 
True-positive (essential both in the model and experiment) 
False-positive (essential in the model, nonessential in experiment) 
True-negative (nonessential in the model and experiment). 
False-negative (nonessential in the model, essential in experiment).
GSMN-TB 1.1 Unified-TB GSMN-MB Unified-MB GSMN-BCG Unified-BCG
True positive 23% 22% 24% 24% 24% 23%
False positive 6% 5% 6% 6% 6% 5%
False negative 19% 18% 19% 17% 20% 19%
True negative 52% 55% 50% 53% 50% 53%
Correct
predictions 75% 76% 75% 77% 75% 76%
p value 0.955 1.000 0.687 0.499 0.863 1.000
5.3.5.3 Receiver operating characteristic curves
Huihai Wu (University of Surrey) generated the ROC curves
ROC curves were plotted for Unified-TB, MB and BCG in order to examine the 
influence of the designated arbitrary cut-offs applied during the analysis of gene 
essentiality predictions (Figure 5-2; Appendices 47-51). The majority of in silico 
mutants generated a predicted growth rate equal to the wild-type or zero (-96%), so 
variation in the in silico growth rate threshold had little influence on the result. However, 
in vitro cut-offs did influence prediction accuracy, with the optimal microarray and p- 
value cut-offs the original values of 0.2 and 0.05 respectively
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Figure 5-2: ROC curve for Unified-TB showing the dependence of prediction results on the 
thresholds for declaring gene essentiality
The plot shows ROC curves for different transposon site hybridization (TraSH) ratio thresholds 
for determination of essential genes in experimental data. Five ROCs are plotted with four 
different TraSH thresholds shown as legend box. Each ROC curve shows the points 
corresponding to True positive rate (sensitivity) and false positive rate (1-specificity) of the 
model predictions obtained for all growth rate thresholds.
■«t
o
■  0.05
■ 0.2 
m  0.5
0.4 0.6 0.8 1.00.0 0.2
False positive rate
5.3.5.4 Distribution plots
Huihai Wu (University of Surrey) generated the distribution plots
Due to the influence of in vitro cut-offs distribution plots were generated for Unified-TB, 
MB and BCG (Figure 5-3; Appendices 5 2 -5 6 ) .  For both TraSH (174) and deep 
sequencing (173) data the two distributions (genes predicted as essential or non- 
essential in silico as compared to the hybridization ratio or p-value) were significantly 
different by means of the Mann-Whitney test (P < 2.2 x 10'^®). This indicates that when 
compared to TraSH data (174) genes predicted as essential in silico have a 
significantly lower median value of insertion probe to genomic probe ratio than 
predicted non-essential genes. Genes considered essential in silico also had a
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significantly lower median p-value than predicted non-essential genes when gene 
essentiality was determined by deep sequencing analysis (173). These results are in 
agreement with the in vitro datasets (173, 174) as a low ratio of insertion probe to 
genomic probe and a low p-value indicates that the mutant strains are depleted after 
gene inactivation or the gene in question can sustain few insertions. Overall, this 
analysis demonstrates the predictive power of the networks using an approach that is 
independent of the cut-offs applied to the in vitro datasets.
Figure 6-3: Distribution of the hybridization ratio of the TraSH library to genomic DMA signal 
recorded in TraSH experiment for genes present in the Unified-TB
The blue line shows the distribution of TraSH ratio among the genes that were predicted as 
essential for growth by the metabolic networks. The red line shows the distribution of TraSH 
ratio among genes predicted to be nonessential. The growth rate threshold is set as 0.001.
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5.3.5.5 Pathway analysis
Examining different areas of metabolism the predictive accuracy (using deep 
sequencing data (173)) of gene essentiality for different metabolic pathways in Unified- 
TB, MB and BCG varied from 59 -  61% for cofactor biosynthesis to 95% in p-oxidation
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of fatty acids (Table 5-6). Approximately half the metabolic pathways generated results 
comparable to the GSMN reaction networks (Table 3-5), with reactions involved in 
CCM, cell wall synthesis, lipid biosynthesis and other functions predicting gene 
essentiality with greater accuracy and cofactor biosynthesis and carbon metabolism 
excluding CCM generating less accurate results.
Table 5-6: Accuracy of gene essentiality predictions for each reaction pathway within the 
network
Pathway Unified-TB Unified-MB Unified-BCG
Amino acid metabolism 72 76 75
Carbohydrate metabolism (excl. CCM) 69 70 66
Cell wall synthesis 94 94 94
Central carbon metabolism 67 68 67
Cofactor biosynthesis 61 62 59
Lipid biosynthesis 80 79 80
Nucleotide biosynthesis 70 70 70
Other 71 69 69
Transport reactions 94 95 95
3-oxidation of fatty acids 95 95 95
5.4 Discussion
Metabolic reaction networks require iterative development in order to continually reflect 
current metabolic knowledge. As well as incorporating novel data, network 
reconstruction may also include the integration of genome scale reaction networks that 
concurrently exist for the same microorganism. The study described here illustrates 
this approach by generating an M. tuberculosis reaction network, with corresponding 
bovine tuberculosis networks, through the integration of two co-existing networks 
(GSMN-TB 1.1 (Appendix 1) and iNJ661 (116)) and the addition of novel data. The 
networks have a broader scope than the preceding networks and reproduce in vitro 
data with similar accuracy to GSMN-TB 1.1 and greater efficiency than iNJ661 (116).
The reconstruction of the Unified reaction networks involved both automated and 
manual processes in order to generate a network that functions as a unique model and 
is free of biochemical inconsistencies. The SuBliMinaL Toolbox (196) facilitated the 
network development process by performing tasks such as: adding annotations from 
external databases for unambiguous identification of model entities, estimating pKas
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and predicting the dominant metabolite protonation state, balancing metabolic 
reactions to ensure the reconstruction is free of stoichiometric inconsistencies that 
violate mass conservation, and automatically merging each model into a single 
consolidated model. Manual curation also standardised features such as metabolite 
names and the Biomass formulation. The implementation of more commonly utilised 
curation methods and network annotations extensively linked to external databases 
has the advantage of enabling unambiguous identification of model entities and creates 
a network more easily accessible to the scientific community.
Due to the differences between concurrent metabolic networks, networks generated for 
the same microorganism may exhibit different properties and predict in vitro data with 
varying efficacy. Therefore, the Unified-TB network, along with the alternative 
M. tuberculosis networks, was validated against high-throughput substrate phenotype 
data, existing large-scale gene essentiality data^ ® ®^ and growth rates for calculated 
substrate uptake rates. The Unified-TB network reproduced these in vitro datasets with 
a high degree of accuracy, generating similar results to GSMN-TB 1.1 and predicting 
with greater accuracy than iNJ661 (116), iNJBGIm (126) and the Metamerge network 
(114). The Unified bovine tuberculosis networks also represented in vitro data 
efficiently, with predictive accuracies comparable to GSMN versions. Consequently, the 
updated reaction networks represent an excellent tool for interrogating existing 
datasets and predicting mycobacterial phenotypes.
The amalgamation of coexisting reaction networks and the implementation of extensive 
links to external databases has been a significant progression in network development, 
as comparison of reaction networks representing the same species is difficult without a 
universal system of annotation. By combining the first two published genome scale 
M  tuberculosis networks we aim to standardise the mycobacterial reaction networks 
and have used a range of techniques to verify that the network accurately 
characterises the tubercle bacillus. Our networks are available to the scientific 
community and continual network curation ensures the incorporation of current 
metabolic theories.
Chapter 6: Final discussion and future 
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m
Metabolic pathways, adapted from KEGG (143)
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6.1 Final discussion and future work
The control of tuberculosis disease, both in humans and in animals, is complicated by 
the lack of certainty regarding the determinants of bacterial pathogenicity. 
Understanding metabolic phenotypes is considered a key aspect of mycobacterial 
research as metabolism and metabolic adaptation to the host environment has been 
highlighted as a key component of the pathogenic strategy of M. tuberculosis (8-12), 
and is also likely to be important for the virulence of M. bovis. A systems biology 
approach provides very effective methods for studying metabolic pathways and 
interrogating the metabolic capabilities of species on a genome wide level. This report 
describes the first genome scale metabolic reaction networks generated for M. bovis 
and M. bovis BCG and their on-going iterative development alongside an 
M. tuberculosis reaction network. The networks describe current biochemical 
knowledge and permit the establishment of defined in silico conditions for investigating 
the metabolic capabilities of these microorganisms. Through their application to 
interrogate high throughput experimental data we have demonstrated a high level of 
predictive accuracy and the potential to generate experimentally testable hypotheses 
which shed new light on metabolic differences between the vaccine, bovine and human 
strains of the tubercle bacillus. The capability to drive model-driven metabolic discovery 
provided further justification for a systems biology approach and demonstrates that the 
reaction networks provide an invaluable tool for investigating the metabolism and 
metabolic differences between M. tuberculosis, M. bovis and M. bovis BCG. To our 
knowledge this is the first time the metabolism of a pathogen and its vaccine strain 
have been compared on a systems level.
The first genome scale metabolic networks for M. bovis and M. bovis BCG (GSMN-MB 
and BCG) instantiate current knowledge on the metabolic differences between human 
and bovine tuberculosis strains, and make an important contribution to our 
understanding of the metabolism of the bovine form of tuberculosis. GSMN-MB and 
BCG also support theories on the evolutionary history of M. tuberculosis, M. bovis and 
M. bovis BCG (16), as the removal of metabolic genes was required in order to model 
M. bovis and M. bovis BCG reaction pathways to metabolic data. Their on-going 
development along with the M. tuberculosis model (115) enabled the networks to 
reflect current metabolic knowledge, removed stoichiometric inconsistencies, 
standardised mycobacterial reaction networks and generated networks more 
convenient for use by the scientific community.
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Interrogation of both GSMN and Unified reaction networks with in vitro data 
consistently generated comparisons with a high degree of accuracy. Additionally, 
comparison of our M. tuberculosis networks with concurrent models for this species 
showed that both the original and updated networks more successfully reproduced 
substrate utilisation, gene essentiality and growth rate experiments than the alternative 
networks. Therefore, our networks accurately represent current metabolic theories on 
the metabolism of these species and are an important development that will assist the 
scientific community in analysing mycobacterial metabolism. All networks are available 
in a variety of formats, although the Unified reaction networks have replaced the GSMN 
models as their reaction network more accurately reflects M. tuberculosis, M. bovis and 
M. bovis BCG metabolism.
The use of large datasets in the interpretation of in siiico networks is a fundamentally 
iterative process with the in vitro data used to detect inconsistencies, identify areas for 
improvement and generate experimentally testable hypotheses. Throughout this project 
the analysis of in vitro datasets evaluated how closely the network predictions matched 
published experimental data and whether the models replicated known metabolic 
features and differences. Interestingly, the M. tuberculosis reaction networks generally 
represented in vitro data slightly better than the bovine tuberculosis networks, 
indicating that further metabolic differences exist between the species that are yet to be 
identified. Consequently, it is likely that some mutation events exert a more extensive 
change on mycobacterial metabolism than identified from enzyme analysis alone. Such 
global effects have previously been shown by the inactivation of pykA in M. bovis (81).
The comparison of datasets also led to the identification of central metabolic pathways 
where current enzymatic knowledge cannot explain the observed metabolic 
phenotypes. For instance, the M. bovis reaction networks were able to utilise glucose 
as a sole carbon source, whereas in vitro the inability to grow on glucose is a key 
characteristic differentiating the species from M. tuberculosis. The hypothesis 
investigated as a result of this observation was that a second metabolic or regulatory 
defect in glucose metabolism contributes to the M. bovis glucose phenotype (80), in 
addition to the inactive pykA. Substrate uptake experiments confirm this theory, with a 
potential defect in glucose transport being identified. Currently no glucose transporters 
have been identified in M. tuberculosis, M. bovis or M. bovis BCG (201) and thus a goal 
of future work is to identify and investigate the genes involved in glucose uptake.
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In addition to predicting M. bovis growth on glucose the reaction networks consistently 
demonstrated that theoretical substrate utilisation capabilities were greater than those 
achieved in vitro] with false positive in siiico predictions mainly involving amino acids 
and carbohydrates. Presumably, the catabolic reactions utilised in siiico are not able to 
support growth in vitro and regulation of central metabolic pathways (which is poorly 
understood (71, 102, 164)) is likely to have a key role in substrate utilisation. These 
discrepancies illustrate a limitation of FBA predictions, in which any route for flux from 
substrates to products may be utilised by the solution if mathematically possible. 
Ideally, genome scale reaction networks would include regulatory features and 
describe gene expression, enzymatic regulation and the dynamic behaviour of cellular 
metabolism. However, detailed parameters for the participating reactions are currently 
unavailable and difficult to measure, with only small reaction subsets (glucose, lactose, 
glycerol, sucrose, and galactose metabolism) in Escherichia coii having been modelled 
in a dynamic manor (213-215).
It is an important goal of future work to investigate the identified discrepancies, as a 
more complete understanding of carbon and amino acid metabolism could shed light 
on the differences in tropism and pathogenicity between M. tuberculosis, M. bovis and 
M. bovis BCG. For instance, the natural loss of pykA from M. bovis strains and the 
inactivation of pykA in M. tuberculosis has a global effect, potentially affecting virulence 
as well as carbon metabolism (81). This mutation event results in the requirement of 
non-glycolytic substrates as carbon sources, as predicted to occur within the host (40, 
94-97), and alters the expression of key metabolic genes {id, pepck, dIaT, Ipd) known 
to affect the virulence of M. tuberculosis in animal studies (9-13, 81). Also, amino acids 
such as serine, aspartate/asparagine, glutamate/glutamine and alanine have been 
shown to be assimilated by M. tuberculosis in the macrophage (216), and our research 
has highlighted differences in the utilisation of amino acids between these 
mycobacteria. The use of ^^0 metabolic flux analysis under different conditions would 
assist in the study of these and other catabolic pathways and shed light on their 
regulation. Such an approach has already been applied to M. tuberculosis and 
M. bovis BCG (164). The investigation of gene knockouts in carbon and amino acid 
metabolism and the identification of amino acids transporters would also enable these 
metabolic pathways to be better understood.
Another goal of future work is the conversion and adaptation of these reaction networks 
to in vivo conditions, as this would provide important new information about the
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metabolism of M. tuberculosis, M. bovis and M. bovis BCG. Under the described in 
vitro conditions the models do not deliver an adequate representation of the metabolic 
processes required by the pathogen in order to infect and persist within a host. 
However, simulation of mycobacteria in vivo is hindered by the poorly defined 
surrounding environment and subsequent uptake of nutrients. Additionally, the 
mathematical basis of the currently achievable constraint-based networks creates 
problems when generating in vivo networks due to the requirement for steady-state 
conditions. Current adaptations of M. tuberculosis networks to in vivo conditions have 
been through the alteration of biomass requirements (115), through enhancing the 
agreement between calculated and in vivo-measured gene essentiality data and by 
incorporating both the pathogen (iNJ661 (116)) and host (macrophage network 
iAB-AM0-141O (217)) (218).
Understanding the metabolism of M. tuberculosis, M. bovis and M. bovis BCG and how 
their metabolic differences relate to pathogenicity is a formidable challenge. The 
biology of both metabolism and pathogenicity is poorly understood and is preventing 
efforts to design more effective vaccines and therapeutic agents. It is likely a 
combination of techniques, including in vitro and in siiico approaches, will be required 
for the generation and interpretation of data that will enable metabolism and its 
contribution to mycobacterial pathogenicity to be deciphered. The systems biology 
approach carried out and outlined as further work utilises both these methods of 
investigation, and compares equivalent studies in order to identify discrepancies for 
further analysis. Consequently this study has, and may further, lead to a greater 
understanding of the metabolic functioning of mycobacteria. Future work aims to 
identify metabolic alterations undergone within the host, with the in siiico comparison of 
pathogenic and vaccine strains in macrophages having the potential to identify novel 
differences in metabolism that may result in pathogenic variations. The information 
learned as a result of these investigations will help to fill the large gaps in our 
knowledge that are hampering efforts to design more effective vaccines and drug 
therapies. Without understanding the biology of a microorganism, the suitability of 
different vaccines and drug therapies cannot be easily predicted. The analysis of the 
metabolic pathways of M. tuberculosis in siiico has already been used to identify 
suitable drug targets (116, 129), with further in siiico investigations likely to advance 
these efforts.
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The results presented here describe novel reaction networks for studying the 
metabolism of bovine tuberculosis, and their continuing development alongside a 
network of M. tuberculosis metabolism. The availability of these networks to the 
scientific community and their iterative development will help to stimulate new 
understanding of the metabolism of these species. A greater understanding of 
metabolism, and in particular the differences between pathogenic and vaccine strains 
of mycobacteria may be useful in directing the rational design of new vaccines and 
drugs.
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